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Abstract 
 
The role of planar cell polarity (PCP) signalling in breast cancer is unclear, as 
evidence shows that activation of this pathway with WNT5A can either promote or 
inhibit progression. Using the 21T cells, which represent distinct stages of breast cancer 
progression when grown in a mouse xenograft model (21PT, atypical ductal hyperplasia; 
21NT ductal carcinoma in situ; 21MT-1, invasive mammary carcinoma), I hypothesized 
that WNT5A will promote progression only when VANGL1, another component of PCP 
signalling, is elevated. 
Each 21T cell line showed distinct stage-specific morphologies when grown in a 
Matrigel ―on-top‖ assay. WNT5A overexpression promoted progression to an invasive 
phenotype in 21NT (ductal carcinoma in situ-like) cells that was partially dependent on 
RHOA, but not in 21PT (atypical ductal hyperplasia-like) cells. VANGL1 overexpression 
alone or with recombinant Wnt5a increased migration but had no effect on invasion in 
21PT cells. Finally, knockdown of WNT5A and VANGL1 separately did not change 
morphology of 21MT-1 (invasive, metastatic) cells; however, WNT5A knockdown was 
incomplete.  
PCP signalling likely plays a role in promoting progression to an invasive 
phenotype but this may be independent of high VANGL1 expression.  
Keywords 
breast cancer progression, invasion, non-canonical Wnt, planar cell polarity, VANGL1, 
WNT5A 
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Chapter 1  
1 Introduction 
Breast cancer continues to be a major health concern among women worldwide. 
In North America, there has been a decreasing trend in the mortality rate of breast cancer 
over the last several decades (American Cancer Society 2012; Canadian Cancer Society’s 
Steering Committee on Cancer Statistics 2012). This is likely due to increased screening 
and improved diagnostic recognition of early curable stages. However, there will still be 
approximately 45 000 deaths due to metastatic breast cancer in North America in 2012 
(American Cancer Society 2012; Canadian Cancer Society’s Steering Committee on 
Cancer Statistics 2012); therefore, there continues to be a need to understand what drives 
the progression of breast cancer. An important event in the progression of breast cancer is 
the transition from earlier non-invasive lesions to an invasive phenotype. 
1.1 Breast cancer progression 
1.1.1 Definition of breast cancer progression 
Evidence has led to a histological model of breast cancer progression in which 
cells from the terminal duct lobular unit give rise to atypical ductal hyperplasia (ADH) or 
atypical lobular hyperplasia (ALH), which can progress to ductal carcinoma in situ 
(DCIS) or lobular carcinoma in situ (LCIS), and eventually to invasive ductal carcinoma 
(IDC) or lobular carcinoma (ILC) respectively (Figure 1.1) (Page et al. 1985; Page and 
Dupont 1993; Lakhani et al. 1995; Allred et al. 2001; Arpino et al. 2005; Allred et al. 
2008). This model of breast cancer progression will be discussed from 
histomorphological and epidemiological perspectives. 
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1.1.2 A histopathological overview of the pre-invasive stages of 
breast cancer progression 
The human breast is composed of thousands of small glands lined by epithelial 
cells that produce milk. These glands are composed of a single terminal duct with 
multiple end acini (terminal ductules in the non-functioning state) and are referred to as 
the terminal duct lobular unit (TDLU). Once milk is excreted from cells of the TDLU, it 
is propagated outward through a series of interconnecting and increasingly larger ducts. 
The TDLU is composed of two cell layers: (a) an inner luminal epithelial layer composed 
of low columnar cells in the terminal duct and cuboidal cells in the acini/terminal 
ductules, and (b) an outer myoepithelial layer directly adjacent to the basement 
membrane. Pre-invasive epithelial lesions are characterized by a neoplastic epithelial cell 
proliferation which remains confined to the ductal-lobular network and does not penetrate 
the basement membrane or invade into the surrounding stroma. 
The two most common types of invasive breast cancer are known as invasive 
lobular carcinoma and invasive ductal (―no special type, NOS‖) carcinoma.  These are 
preceded by pre-invasive lobular and ductal neoplasias respectively.  Both types of breast 
cancers arise in the TDLU and the distinction between the two is based on morphological 
differences of the cells (Wellings and Jensen 1973; Wellings et al. 1975). Specifically, 
the lobular morphology consists of small, non-polarized cells that are discohesive, with 
vacuolated cytoplasm and a high nuclear to cytoplasmic ratio, resembling cuboidal cells 
of breast acini/terminal ductules.  In contrast, the ductal morphology consists of larger, 
polarized cells, in cohesive groups that resemble columnar cells of terminal ducts. The 
pre-invasive lobular lesions include atypical lobular hyperplasia (ALH) and lobular 
carcinoma in situ (LCIS). Pre-invasive ductal lesions are thought to progress from flat 
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epithelial atypia (FEA), to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ 
(DCIS). In addition, although more controversial, there is some evidence that usual ductal 
hyperplasia (UDH) and an entity known as ―unfolded lobules‖ may in some instances 
also be considered early stages of breast cancer progression (Arpino et al. 2005; Sgroi 
2010). 
FEA, ADH, and DCIS are considered non-obligate precursors of invasive ductal 
carcinoma (IDC). FEA is characterized by a proliferation and replacement of luminal 
cells of the TDLU by one or more layers of columnar epithelial cells that exhibit low-
grade cytological atypia (Schnitt 2003). The cells of FEA do not fill the TDLU but grow 
as either a single cell layer or multiple cell layers  (Lerwill 2008). FEA by present 
definition is comprised of both columnar cell change with atypia and columnar cell 
hyperplasia with atypia. Columnar cell change with atypia is characterized by TDLUs 
that display dilated acini/ductules lined by one or two layers of columnar epithelial cells. 
Columnar cell hyperplasia with atypia is used to describe TDLUs that display dilated 
acini/ductules lined by more than two cell layers of atypical columnar cells. Like FEA, 
ADH is also characterized by low-grade cytological atypia, but differs from FEA in that 
it exhibits architectural abnormalities such as solid patterns with even cell placement, 
punched-out secondary lumina, rigid bridging, and cribriform or micropapillary 
morphologies. The differences between ADH and DCIS are based upon the nature of the 
atypia and the extent of epithelial proliferation (Tavassoli and Norris 1990; Page and 
Rogers 1992). DCIS is classified based on cytomorphological (low, intermediate, or high 
nuclear grade) and architectural features, as well as the presence or absence of luminal 
necrosis, all of which have been associated with outcome. Comedo-type DCIS consists of 
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cells that appear cytologically malignant and are associated with abundant central luminal 
necrosis. Comedo-type DCIS is generally more aggressive and is associated with high or 
(according to some authors) intermediate nuclear grade DCIS. Lastly, important 
distinguishing factors between DCIS and IDC are the complete loss of the outer 
myoepithelial layer in the latter, with extension of neoplastic cells into the surrounding 
stromal compartment, beyond the basement membrane (Pinder and Ellis 2003). 
The spectrum of lobular neoplasias includes ALH and LCIS, both of which are 
considered non-obligate precursors of invasive lobular carcinoma (ILC) (Marshall et al. 
1997; Venkitaraman 2010). The main histological distinction between ALH and LCIS is 
based on the amount that the TDLU is filled by neoplastic cells and the amount the 
lobular unit becomes distended as a result (Page et al. 1985). In ALH, the TDLU is 
colonized by a homogenous cell population of small, round, non-polarized, loosely 
cohesive cells that have a high nuclear to cytoplasmic ratio. The proliferation of ALH is 
limited and leaves the acinar/ductular lumina somewhat intact. Conversely, cells of 
classical LCIS are cytomorphologically similar to ALH, but proliferation is extensive 
enough to completely fill and distend the TDLU. Variants of LCIS have been described, 
including a pleomorphic variant, which consists of medium- to large-sized cells, with 
pleomorphic nuclei, and LCIS with zonal (―comedo type‖) necrosis  (Eusebi et al. 1992; 
Weidner and Semple 1992). 
1.1.3 Epidemiological evidence of breast cancer progression 
Epidemiological studies have provided support for a linear model of breast cancer 
progression. Through long term cohort studies it has been shown that having a previous 
ADH or DCIS diagnosis greatly increases the risk of developing invasive mammary 
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carcinoma, up to 4-5 times for ADH and up to 8-10 times for DCIS compared to the 
general population (Page et al. 1985; Page and Dupont 1993; Fitzgibbons et al. 1998). In 
addition, the relative risk positively correlates with grade, extent, and presence of zonal 
necrosis. Similarity, the risk of invasive disease in women diagnosed with LCIS (classic 
type) is estimated at 8-10 times greater than women in the general population 
(Fitzgibbons et al. 1998). The relative risk associated with a finding of FEA is not yet 
well-established, but studies to date suggest that the risk for developing DCIS or invasive 
mammary carcinoma varies from a slightly increased risk to an increase in risk similar to 
ADH (Schnitt 2003; Martel et al. 2007; Kunju and Kleer 2007; Lerwill 2008). Although 
epidemiologic data would suggest possible precursor status of usual ductal epithelial 
hyperplasia as well (1.5-2 fold increased risk for mammary carcinoma), molecular (loss 
of heterozygosity) studies indicate that this is likely a rare event (Ellis 2010). 
1.1.4 Molecular evidence of ductal and lobular carcinoma 
progression 
The histological patterns observed during breast cancer progression are likely 
rough phenotypic indications of underlying molecular changes. There is interest in 
identifying the cellular and molecular events involved to determine which lesions are 
more likely to progress. An important barrier in understanding these changes has been the 
inability to accurately assess the molecular events as they relate to progression. Highly 
specific tissue-microdissection technologies and rapidly evolving high-throughput 
genomic and transcriptomic analyses have combined to identify a number of genomic and 
gene-expression correlates between different stages of breast cancer. 
DCIS forms a spectrum of neoplastic lesions, with some lesions behaving more 
aggressively than others. These different behaviours are to some degree associated with 
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Figure 1.1 Traditional linear model of breast cancer progression. Multiple lines of 
evidence (histomorphological, immunohistochemical, and molecular) support this model. 
Molecular alterations occurring in the normal terminal duct lobular unit (TDLU) can 
result in flat epithelial atypia (FEA). FEA may lead to additional changes that give rise to 
atypical ductal hyperplasia and ductal carcinoma in situ, upon which subsequent 
alterations in turn give rise to invasive ductal carcinoma (middle). Likewise, molecular 
alterations occurring in the normal TDLU result in atypical lobular hyperplasia, which 
can give rise to lobular carcinoma in situ, upon which subsequent alterations gives rise to 
invasive lobular carcinoma (top). There is some evidence that usual ductal hyperplasia 
may in some instances also be considered as an early stage of breast cancer progression 
(bottom) (from MacMillan et al. 2012). 
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morphologic characteristics, as described above; however, it has been further revealed 
that different morphological subtypes of DCIS reflect distinct genomic alterations (Figure 
1.2). For example, comparative genomic hybridization (CGH)-based studies of DCIS 
revealed frequent loss of 16q in low- and intermediate-grade DCIS and gain of 1q and 
loss of 11q in intermediate-grade DCIS (Buerger et al. 1999; Simpson et al. 2005). 
Additionally, high-grade DCIS was characterized by frequent loss of 8p, 11q, 13q, and 
14q; gains of 1q, 5p, 8q, and 17q; and amplifications of 17q12 and 11q13 (Buerger et al. 
1999). Further CGH analysis comparing DCIS and IDC revealed an almost identical 
pattern of genetic variations (Buerger et al. 1999; Buerger et al. 2001) and there is also a 
correlation between copy number variations and progression (Yao et al. 2006). Together, 
these data support the view that DCIS is a direct precursor to IDC and that distinct 
genetic abnormalities are reflected by nuclear grade within the morphological spectrum 
of DCIS. 
A number of loss of heterozygosity (LOH)-based and CGH-based studies support 
the hypothesis that ADH is a precursor to low grade-DCIS. For example, LOH in regions 
16q and 17p in ADH is similar to the variations observed in low grade-DCIS (Lakhani et 
al. 1995; O'Connell et al. 1998; Amari et al. 1999). Given that ADH and low-grade DCIS 
share many architectural and cytological features (Tavassoli and Norris 1990; Page and 
Rogers 1992), it makes sense that they share common chromosomal abnormalities. This 
supports the presumed sequence of progression of ADH to low-grade DCIS; however, the 
progression to high-grade DCIS is less clear. In terms of histological presentations and 
genetic aberrations, high-grade DCIS is more heterogeneous than low- and intermediate-
grade DCIS. Despite the greater intricacy of the pattern of genetic aberrations found in 
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high-grade DCIS (those with 17q12 amplifications), deletions of 16q are less frequent, 
suggesting that the majority of high-grade DCIS lesions arise de novo. 
There is also molecular evidence suggesting that FEA is a precursor to ADH 
and/or low-grade DCIS. It has been shown that FEA has similar genetic alterations 
compared to ADH and both low-grade DCIS and low-grade invasive carcinoma (Moinfar 
et al. 2000). There is commonly a LOH at chromosome 16q in FEA, low-grade DCIS, 
and low-grade IDC (Moinfar et al. 2000) and there are comparable chromosomal copy 
number gains and losses present in FEA, ADH, and low-grade DCIS (Simpson et al. 
2005). A number of immunohistochemical approaches have also linked FEA, ADH, and 
low-grade DCIS. For example, the atypical/neoplastic cells of all three of these pre-
invasive lesions show the same high-level expression of estrogen receptors, progesterone 
receptors and cytokeratin 19 (Oyama et al. 2000; Simpson et al. 2005), an increase in 
expression of cyclin D1 (Oyama et al. 2000), as well as identical negativity for 
cytokeratin 5/6 (Simpson et al. 2005) and Human Epidermal Growth Factor Receptor 2 
(HER2) (Kusama et al. 2000; Simpson et al. 2005). These data support the view that FEA 
may be a precursor to ADH and low-grade DCIS. 
Much of the research on understanding the gene-expression alterations that occur 
during the early pre-invasive stages of breast cancer have focused on the neoplastic 
epithelial cells of ADH and DCIS (Ma et al. 2003; Ma et al. 2009). For example, a 
patient-matched microdissection and microarray-based study showed that marked 
transcriptional alterations occur between normal TDLUs and ADH, which are sustained 
in DCIS and IDC (Ma et al. 2003). However, in several studies, there were no major 
transcriptional profile changes between the pre-invasive and invasive stages (Ma et al. 
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2003; Porter et al. 2003; Ma et al. 2009). This has led these authors to suggest that both 
pre-invasive and invasive stages of progression are clonal in origin and that genes 
expressed during ADH and DCIS may be responsible for progression. A number of 
studies have linked gene expression patterns during early stages of progression to the risk 
of developing IDC and metastasis (van de Vijver et al. 2002; Paik et al. 2004; Goetz et al. 
2006; Jerevall et al. 2008); however, there is a need clinically to further identify and 
characterize reliable markers of risk for progression. 
Distinct differences in gene expression are also associated with grade (Ma et al. 
2003; Desmedt and Sotiriou 2006; Sotiriou et al. 2006). For example, distinct gene-
expression patterns are present in low- and high nuclear-grade DCIS (Ma et al. 2003) 
similar to what is observed in IDC. Additionally, ADH and low-grade DCIS share gene-
expression patterns associated with ER expression, whereas high-grade DCIS have a 
gene-expression pattern more associated with the cell-cycle and mitosis (Ma et al. 2003). 
In a similar respect, gene expression analysis of intermediate-grade DCIS show a 
combination of low- and high-grade characteristics (Ma et al. 2003; Sotiriou et al. 2006). 
These gene expression analyses support the view that low- and high-grade breast cancers 
arise from normal TDLUs through distinct molecular pathways (Figure 1.2). Defining 
distinct molecular pathways and breast cancer subtypes continues to be an evolving field 
as stratification of breast cancer into distinct subgroups and their molecular drivers 
involves an integrated view of the both the genome and transcriptome (Curtis et al. 2012). 
CGH-based analyses of ALH and classic LCIS has revealed a similar pattern of 
chromosomal variation – loss of 16p, 16q, 17p, and 22q (Lu et al. 1998) in both. Further 
studies have identified a common loss in 16q in ALH, LCIS, and classic ILC (Mastracci 
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et al. 2006; Morandi et al. 2006). This supports the view that ALH and LCIS are closely 
related lesions and that all three (ALH, LCIS, and classic ILC) represent a progression 
continuum. Additionally, gene expression analysis of LCIS and classic ILC shows a 
pattern that is correlated with low-grade DCIS and IDC (Cao et al. 2008). Taken together, 
these studies support a common –16q, low-grade molecular pathway that includes ALH, 
LCIS, and classic ILC, as well as FEA, ADH, low-grade DCIS and low-grade IDC. 
A small subset of ILCs shows a more aggressive clinical course, and consists of 
neoplastic lobular cells with more marked nuclear atypia (pleomorphic ILC). These 
cancers share common genetic variations with classic ILC – e.g. loss of 16q and gain of 
1q; as well as common features of high grade IDC – e.g. amplification of 17q12 
(Middleton et al. 2000; Simpson et al. 2008). However, a CGH-based study revealed that 
overall genetic variations of pleomorphic ILC are more closely correlated to those 
observed in classic ILC compared to IDC (Simpson et al. 2008). This suggests that 
pleomorphic ILC has a common molecular pathway of progression to that of classic ILC, 
that later accumulates alterations more characteristic of a high grade lesion (Figure 1.2). 
Similarly, there is CGH evidence that variant LCIS (pleomorphic LCIS, LCIS with 
necrosis) is of a common molecular background to classic LCIS (loss of 16q, gain of 1q), 
but that it is also associated with numerous further genetic aberrations that are more 
characteristic of a high grade lesion (Boldt et al. 2010). 
1.1.5 The transition from pre-invasive to invasive breast cancer 
The transition from a pre-invasive to an invasive phenotype occurs when cells of 
DCIS (or LCIS) invade through the basement membrane and into the surrounding stromal 
tissue, thus representing a key event in the progression of breast cancer. There is evidence 
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Figure 1.2 A multistep model of human breast cancer progression based on 
immunohistochemical and gene-expression data. Molecular events that occur in the 
normal terminal duct lobular unit (TDLU—blue rectangle) give rise to two distinct 
molecular pathways (low- and high-grade molecular pathways). Linear pathological 
progression occurs from normal TDLUs to invasive breast cancer (solid arrows) and 
intrastage progression occurs within ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC) (dotted arrows). The low-grade molecular pathway is characterized by 
loss of 16q, gain of 1q, and estrogen receptor (ER) and progesterone receptor (PR) 
positivity and is observed during pre-invasive and invasive stages of both ductal and 
lobular lesions (yellow rectangles). The high-grade molecular pathway is characterized 
by amplification of 17q12 and 11q13, loss of 13q, and ER/PR negativity (red rectangles). 
Pleomorphic lobular lesions [atypical lobular hyperplasia (ALH), lobular carcinoma in 
situ (LCIS), and invasive lobular carcinoma (ILC)] resemble high-grade tumors; 
however, immunohistochemical and genetic analyses support an association with the 
low-grade molecular pathway. Abbreviations: ADH, atypical ductal hyperplasia; FEA, 
flat epithelial atypia (modified from MacMillan et al. 2012). 
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that the tumor microenvironment is important during progression and that molecular 
changes in non-neoplastic cells (Allinen et al. 2004; Hu et al. 2005; Ma et al. 2009), in 
addition to neoplastic epithelial cells, have the potential to drive progression (Orimo et al. 
2005; Karnoub et al. 2007; Hu et al. 2008; Sung et al. 2011). For example, in a cell line 
model for DCIS (Hu et al. 2008), the transition from DCIS to IDC did not require 
additional molecular alterations within the neoplastic epithelial cells, but rather 
progression to IDC was promoted by fibroblasts and suppressed by myoepithelial cells 
that make up the stromal and periductal microenvironment of DCIS. Molecular profiling 
of isolated epithelial and myoepithelial cells identified a signalling interaction network 
involving transforming growth factor β (TGF-β), hedgehog, cell adhesion molecules and 
p63, which was required for the differentiation of myoepithelial cells. Elimination of this 
signalling network resulted in loss of the myoepithelial cells and progression to an 
invasive phenotype (Hu et al. 2008). Similarly, the establishment of the self-sustaining 
TGF-β and stromal cell-derived factor 1 (SDF-1) autocrine signalling loops in resident 
mammary myofibroblasts can give rise to carcinoma-associated myofibroblasts that 
promote progression to invasive mammary carcinoma (Kojima et al. 2010). In addition, 
carcinoma-associated fibroblasts may mediate tumor growth and angiogenesis through 
the secretion of SDF-1 by acting directly on neoplastic epithelial cells via the chemokine 
(C-X-C motif) receptor 4 (CXCR4) and by recruiting endothelial progenitor cells, 
respectively (Orimo et al. 2005). In addition, tumor-associated macrophages can have 
progression-promoting effects through the secretion of immunosuppressive cytokines, the 
release of free radicals such as nitric oxide and hydrogen peroxide, and the secretion of 
angiogenic factors. It has been suggested that these signalling mechanisms may be useful 
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as therapeutic targets to block the development of tumor-promoting stromal cells 
(Malmberg 2004). 
Studies such as these have changed our view of breast cancer progression as 
solely an epithelial/tumor cell-driven process. Two possible models of the DCIS-to-IDC 
transition (―escape‖ vs. ―release‖) have been suggested (Polyak and Hu 2005). The 
―escape‖ model proposes that genetic alterations accumulate in a subpopulation of 
neoplastic epithelial cells which provides them with the ability to disrupt the 
myoepithelial layer and invade through the basement membrane into the surrounding 
stromal compartment. In contrast, the ―release‖ model proposes that degradation of the 
basement membrane and subsequent invasion is due to alterations in the tumor 
microenvironment, particularly in the myoepithelial cells, myofibroblasts, fibroblasts, and 
tumor infiltrating inflammatory cells. What is actually occurring is most likely a 
combination of both models whereby changes in neoplastic epithelial cells and non-
neoplastic cells of the tumor microenvironment both contribute to the transition from pre-
invasive to invasive disease. 
1.2 Cell migration and metastasis 
1.2.1 Cell migration 
Cell migration is an important mechanism in a number of biological processes. 
For example, in the event that the immune system is required to respond to a pathogen, 
the body relies on the ability of immune cells, such as natural killer cells, to migrate to 
the site of infection (Walzer and Vivier 2011). Endothelial cell migration, mediated by 
endothelial growth factor (VEGF) and mitochondrial reactive oxygen species, is required 
during the repair of damaged blood vessels that have become injured from atherosclerosis 
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(Wang et al. 2011). During spermatogenesis, germ cells migrate across the seminiferous 
epithelium and use important mediators such as matrix metalloproteases (MMPs) in order 
to invade through this dense tissue (Chen et al. 2011). A number of processes during 
development also require cell migration. For example, the disrupted function of the 
planar cell polarity (PCP) pathway, which is important for polarized cell movements, is 
implicated in neural tube defects (Wu et al. 2011). Cell migration is also important in 
ductal morphogenesis in the breast. For example, cells in elongating mammary ducts 
reorganize into a multilayered epithelial cell layer and migrate collectively. Initiation of 
the duct required important effectors of migration including Rac and myosin light-chain 
kinase whereas polarization to a bilayer depended on RHO-associated protein kinase 
(ROCK) (Ewald et al. 2008). It is evident that cell migration is an important underlying 
mechanism during a number of normal physiological processes. However, these same 
mechanisms can also be used by cancerous cells to migrate and invade during metastasis.  
1.2.2 Cell migration and cancer metastasis 
Metastasis is the spread of cancer from the primary tumor to a secondary site and 
consists of several consecutive, potentially rate-limiting steps (Talmadge and Fidler 
2010). First, cancer cells migrate and invade from the primary tumor into surrounding 
stromal compartment. Next, they undergo intravasation into the blood or lymphatic 
vessels. Once they are in the circulation, cancer cells extravasate out of vessels at the 
secondary site using migration and invasion mechanisms. Finally, the cancer cells 
colonize and grow at the secondary site (Talmadge and Fidler 2010). Inhibiting the 
migration and invasion into the stroma and away from the primary tumor, one of the 
earliest steps in metastasis, can prevent the rest of the metastatic cascade (Zijlstra et al. 
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2008), supporting the idea that tumor cell migration is required for metastasis (Palmer et 
al. 2011; Shieh et al. 1999). 
1.2.3 RHO family of GTPases 
As noted above, cell migration is a key process in the metastasis of cancer. The 
RHO-family GTPases (Ras-homology-family of guanosine triphosphates) regulate many 
proteins involved in cell migration and are important downstream effectors in the PCP 
pathway (see section 1.4.2). The prototypical RHO-family GTPases are: Cdc42, Rac1, 
and RHOA. These proteins are themselves regulated by RHO-GEFs (guanine exchange 
factors) and RHO-GAPs (GTPase activating proteins). RHO-GEFs exchange a GDP for a 
GTP, which places the RHO-GTPase in its active state. Conversely, RHO-GAPs 
inactivate RHO-GTPases by removing a phosphate group from GTP making it a GDP 
(Tomar and Schlaepfer 2009). RHO-GTPases can be activated upon adhesion of the cells 
to the extracellular matrix (ECM), which initiates cell migration (Tomar and Schlaepfer 
2009).  
After contact with the extracellular matrix, Cdc42 activates actin polymerization, 
which in turn produces actin-rich filopodia (Olson and Sahai 2009). Filopodia are used 
for directional cell migration and the presence of filopodia is associated with increased 
invasion (Olson and Sahai 2009; Pan et al. 2011). Cdc42 also mediates lamellipodia 
formation in 2D environments (Olson and Sahai 2009). Lamellipodia formation may 
correspond to invadopodia formation that is seen in 3D environment since both rely on 
similar actin-related protein 2/3 (Arp2/3)-mediated actin polymerization (Olson and 
Sahai 2009). 
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Similar to Cdc42, Rac1 is also activated upon cell adhesion to extracellular matrix 
components and can induce formation of lamellipodia in migrating cells through Arp2/3 
(Olson and Sahai 2009). RHOA has two functions during cell migration. It is involved in 
forming stress fibres to facilitate cell adhesion during the initial phase of migration and it 
induces cell contractility during later phases (Tomar and Schlaepfer 2009), both of which 
are mediated by a downstream effector protein ROCK. 
ROCK inhibits the depolymerisation of actin filaments by activating LIM kinase, 
which in turn phosphorylates cofilin thereby inactivating its actin-depolymerization 
activity. This results in an increase in the number of stable actin stress fibres that are 
required during cell adhesion (Riento and Ridley 2003; Maekawa et al. 1999). ROCK 
also regulates cell migration through the promotion of cellular contraction by increasing 
the activity of the motor protein myosin II, using one of two different mechanisms. 
Firstly, ROCK can phosphorylate myosin light chain which increases the myosin II 
ATPase activity, resulting in the net shortening of actin fibres. Secondly, ROCK can 
inactivate myosin light chain phosphatase, leading to increased levels of phosphorylated 
myosin light chain (Riento and Ridley 2003).  
The expression of Rac1 is increased in human gastric cancer and expression is 
correlated with tumor grade (Walch et al. 2008). In addition, active Rac1 expression is 
associated with increased grade in upper urinary tract cancers and is involved in lymph 
node metastasis (Kamai et al. 2010). Immunohistochemical analysis of hepatocellular 
carcinoma tissue samples established an association between RHOA expression and poor 
differentiation. It was also shown that RHOA was required for cell migration of 
hepatocellular carcinoma cell lines (Gou et al. 2011). Recently, RHOA was found to be a 
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downstream effector of PCP mediated migration of the MDA-MB-231 breast cancer cell 
line (Zhu et al. 2012). The above implicates a role for RHO-family GTPases in cancer 
cell migration and metastasis. 
1.3 Models and methods used to study breast cancer 
progression 
1.3.1 In vitro breast cancer progression models 
In order to study the pre-invasive stages of breast cancer progression, several in 
vitro models have been developed. Most take advantage of established human breast 
epithelial cell lines which have been altered with activated oncogenes that drive 
production of these pre-invasive phenotypes (Weaver et al. 1995; Miller et al. 2000; 
Stampfer and Yaswen 2000; Briand and Lykkesfeldt 2001). 
One in vitro model of breast cancer progression is the HMT-3522 series cell lines 
(Weaver et al. 1995; Briand and Lykkesfeldt 2001), which consists of three cell lines 
derived from a single patient presenting with fibrocystic change. The HMT-3522/S1 cell 
line was produced during in vitro culture of the explant and was shown to be non-
tumorigenic in a mouse xenograft model; whereas the HMT-3522/S2 cell line was 
established after an epidermal growth factor (EGF)-independent growth selection of the 
HMT-3522/S1 cell line and was shown to be tumorigenic. The third cell line, HMT-
3522/T4-2, was derived from a HMT-3522/S2 tumor and is considered to be the most 
tumorigenic of the three cell lines. The HMT-3522 cell lines have undergone malignant 
transformation in vitro without being exposed to known carcinogenic agents and this 
transformation resembles some aspects of progression during pre-invasive breast disease 
(Briand and Lykkesfeldt 2001). Similarly, the MCF10AT series cell lines represent a 
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range of pre-invasive breast lesions (Miller et al. 2000; Stampfer and Yaswen 2000).  The 
MCF10A cells, also derived from a patient with fibrocystic change, are benign, 
immortalized breast epithelial cells. The MCF10AT cell line was derived from these cells 
by ras transformation. Subclones of the MCF10AT cells have generated a number of pre-
invasive lesions including ADH and DCIS (Miller et al. 2000; Stampfer and Yaswen 
2000). Both the HMT-3522 and the MCF10AT cell lines have proven useful; however, 
both model systems suffer from disadvantages. Both show mixed phenotypes and lack of 
stability of the phenotypes after culture. Additionally, the HMT-3522 cell lines lack a 
pre-DCIS stage, while the MCF10AT series is ras-transformation dependent, an 
uncommon event in spontaneous human breast cancers. 
The 21T series cell lines, which were all derived from a single patient with 
metastatic breast cancer, represent a human breast cancer progression series (Band et al. 
1990; Souter et al. 2010). When grown in the mammary fat pad of nude mice, each cell 
line can reproduce a distinct stage of progression. For example,  21PT cells are non-
tumorigenic and generate lesions of ADH, 21NT cells form lesions with the morphology 
of DCIS, and 21MT-1 cells generate IDC and are both tumorigenic and metastatic 
(Souter et al. 2010). 
1.3.2 Matrigel and 3D in vitro culture 
In vitro systems are very useful for high throughput studies. However, it has been 
shown that when grown in 2D in vitro culture, cell lines can have distinctly different 
morphology and genetic profiles compared to in vivo growth (Shaw et al. 2004; Fournier 
and Martin 2006; Kenny et al. 2007; Lee et al. 2007; Hebner et al. 2008; Martin et al. 
2008). Also, important signals released by the extracellular matrix, which control normal 
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homeostasis and tissue phenotypes, are lost when cells are cultured in 2D. When cells are 
cultured in a laminin-rich extracellular matrix, these signals remain intact (Lee et al. 
2007). By allowing cells to grow in a 3D conformation in contact with extracellular 
matrix proteins, certain characteristics of cell morphogenesis, proliferation, apoptosis, 
and invasiveness may be studied in a highly controlled 3D environment. In fact, there 
have been many studies using 3D systems to examine molecular controls of 
morphogenesis in normal and neoplastic breast epithelial cells (Fauquette et al. 1997; 
Weaver et al. 1997; Wang et al. 1998; Debnath et al. 2002; Hebner et al. 2008). There has 
been limited use of 3D in vitro systems to directly study the progression through the pre-
invasive to invasive stages of breast cancer; however, use of the HMT-3522 cell lines 
(Rizki et al. 2008) and the 21T cell lines (Souter et al. 2010) in 3D systems has proven 
useful in identifying potential regulators of progression. 
1.3.3 The human 21T breast epithelial cell lines represent a 
progression series 
As mentioned above, the 21T cell lines, which were derived from a single patient 
with metastatic breast cancer, represent a human breast cancer progression series (Band 
et al. 1990; Souter et al. 2010). For example, the 21PT cell line was found to be 
consistently non-tumorigenic and non-metastatic when injected into the mammary fat 
pads of nude mice and, upon further histological examination, there were some lesions 
mimicking ADH. When 21PT cells were grown embedded in 3D Matrigel, they 
developed in colonies capable of forming well-defined acinar structures, while 
maintaining cell polarity. Many of these colonies showed a mixture of cells with normal-
appearing and atypical nuclei (Souter et al. 2010). 
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In contrast, the 21NT cells were found to be tumorigenic and non-metastatic when 
injected into the mammary fat pad of nude mice and the lesions that formed had a 
histology representative of DCIS. The involved ducts showed a uniform neoplastic cell 
population, with intermediate and high grade nuclei, solid and cribriform architectural 
patterns, with zonal necrosis. When 21NT cells were grown embedded in 3D Matrigel, 
the colonies that formed showed features consistent with DCIS, including nuclear atypia 
in all of the constituent cells and a spherical, non-infiltrative behaviour (Souter et al. 
2010). 
The 21MT-1 cells, when injected into the mammary fat pad of nude mice, were 
found to form tumors showing invasive mammary carcinoma, most with associated DCIS 
(intermediate and high nuclear grade). When 21MT-1 cells were grown embedded in 3D 
Matrigel, they formed highly disorganized, non-spherical colonies, with almost no lumen 
formation within the colonies themselves, which is consistent with the behaviour 
observed in the nude mouse xenografts (Souter et al. 2010). 
1.3.4 The 21T cell lines show stage-specific gene expression 
patterns 
Microarray analysis was used to identify unique differential gene expression 
patterns between the three 21T cell lines (Souter et al. 2010). Interestingly, differences in 
Wnt pathway components, such as changes in WNT5A and VANGL1 expression, were 
found between the 21PT and 21NT cell lines, which represent ADH and DCIS 
respectively. This is consistent with a number of recent studies implicating Wnt 
signalling pathways in breast cancer progression (Mohinta et al. 2007). One particular 
(non-canonical) Wnt pathway, the planar cell polarity (PCP) pathway, which involves the 
Wnt ligand WNT5A, has been shown to have both inhibitory and promoting effects in 
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cancer, depending on the context (Kikuchi and Yamamoto 2008). It has been suggested 
that the PCP pathway has a predominately inhibitory role early in progression by 
inhibiting canonical Wnt signalling and β-catenin stabilization. However, during later 
stages of progression, the PCP pathway may itself drive progression by stimulating cell 
migration through the downstream effectors RHOA and Rac1 (Wang 2009). In the 21T 
series cell lines, WNT5A expression was found to be decreased from the 21PT cells to 
the 21NT cells (ADH to DCIS transition), and was found to be increased from the 21NT 
cells to the 21MT-1 cells (DCIS to IMC transition). VANGL1 expression was found to 
be increased from the 21PT cells to the 21NT cells and remained relatively high in the 
21MT-1 cell line (Souter et al. 2010). 
1.4 Non-canonical Wnt/PCP signaling 
1.4.1 An overview of Wnt signaling 
Wnt signalling comprises a number of highly conserved cell signalling pathways 
that control cellular processes that are fundamental to embryogenesis such as 
proliferation, differentiation, polarity, and migration. However, aberrant Wnt signalling 
has been implicated in a number of different pathologies including cancer (Logan and 
Nusse 2004).  
There are two distinct patterns of Wnt pathway signalling: the canonical Wnt/β-
catenin-dependent pathway and non-canonical Wnt/β-catenin independent pathways. 
Both make use of a large family of cysteine-rich secreted ligands with at least 19 
members in humans. The Wnt ligands themselves have been divided into two groups 
based on whether they induce transformation in a mouse mammary epithelial cell line; 
this Wnt-induced transformation is associated with the ligand’s ability to activate specific 
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pathways (Wong et al. 1994). Highly transforming Wnt ligands include Wnt1, Wnt3, 
Wnt3a, and Wnt7a and these have been shown to activate the canonical Wnt/β-catenin-
dependent pathway. Activation of the canonical Wnt/β-catenin-dependent pathway 
mediates β-catenin localization to the nucleus where it activates various transcription 
factors affecting gene expression (Kikuchi et al. 2009; MacDonald et al. 2009). Non-
transforming or partially-transforming Wnt ligands include Wnt2, Wnt4, Wnt5a, Wnt5b, 
Wnt6, Wnt7b, and Wnt11 and these have been shown to activate non-canonical Wnt/β-
catenin independent pathways. 
Non-canonical Wnt signalling itself is made up of a number of different signalling 
pathways (Semenov et al. 2007), the most characterized being the Wnt/Ca
2+
 pathway and 
the Wnt/planar cell polarity (PCP) pathway. During Wnt/Ca
2+
 signalling, Wnt ligand 
binding to the Frizzled (Fzd) receptor activates phospholipase C, which leads to an 
increase in intracellular Ca
2+
 levels and activation of protein kinase C (PKC). This 
signalling pathway is involved during development but has also been implicated in cancer 
(Kohn and Moon 2005). For example, WNT5A induces an epithelial to mesenchymal 
transition through PKC/Ca
2+
 signalling, which in turn promotes melanoma metastasis 
(Dissanayake et al. 2007). 
Among the non-canonical Wnt pathways, the Wnt/PCP pathway was the first 
described and the most widely studied (Simons and Mlodzik 2008; Zallen 2007). 
Drosophila has served as a useful model for PCP signalling because planar cell polarity 
occurs in a number of visible structures. The term ―planar cell polarity‖ was derived from 
the tissue polarity necessary to generate polarization within the plane of the epithelium 
(Nubler-Jung et al. 1987). An analogous planar cell polarity signalling pathway was also 
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observed in vertebrates, involved in processes such as convergent extension (CE) 
movements of mesenchymal cells during gastrulation, ordered arrangement of hairs of 
mammalian skin and cilia of the respiratory tract, and orientation of axon extension 
(Goodrich 2008). 
1.4.2 PCP signaling 
The PCP pathway is highly conserved and is made up of consecutive steps that 
establish polarity in individual cells, ultimately giving whole tissues direction and 
polarity (Tree et al. 2002). Firstly, upstream PCP components, such as WNT5A, provide 
long range signals that establish overall polarity within the developing tissue (Strutt and 
Strutt 2005). Secondly, core PCP components, such as Fzd, Dishevelled (Dvl), Clsr, 
VANGL1, and Prickle, interpret these long range singles and establish planar polarity 
within single cells.  Finally, downstream effectors, such as Daam1, RHOA, Rac1, ROCK, 
and c-Jun N-terminal kinase (JNK), use the signals mediated by the upstream and core 
PCP components to regulate cell polarity and migration by acting directly on the 
cytoskeleton (Figure 1.3). The RHO-family GTPases RHO and Rac are particularly 
important in mediating downstream PCP signalling (Schlessinger et al. 2009). Taken 
together, PCP pathway components induce intracellular cytoskeleton rearrangements and 
affect cell behaviours by transducing extracellular polarity signals and integrating both 
extracellular and intracellular proteins.  
1.4.3 PCP signaling and cancer 
The role of non-canonical Wnt signalling is critical in the formation of a number 
of embryonic tissues and organs (Wang and Steinbeisser 2009; Karner et al. 2006; 
Barrow 2006). These embryonic processes may, however, be co-opted in the course of 
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tumor progression. Many conserved signalling pathways that are important during 
development, including Wnt, Hedgehog, and Notch, often become aberrant during cancer 
development which supports the theory that tumorigenesis and development share similar 
signalling processes (Kho et al. 2004). Even though canonical Wnt/β-catenin signalling 
has been shown to be a critical player during tumorigenesis/cancer progression 
(Takemaru et al. 2008), there has been accumulating evidence that PCP signalling may 
also play a role (Katoh 2005; Kikuchi and Yamamoto 2008). 
1.4.4 PCP signaling and metastasis 
Breast cancer metastasis accounted for approximately 45 000 deaths in North 
American in 2012 (American Cancer Society 2012; Canadian Cancer Society’s Steering 
Committee on Cancer Statistics 2012). As breast cancer progresses, from in situ to 
invasive disease, cells may develop the ability to invade through the basement membrane 
and into the surrounding stromal compartment, eventually forming secondary tumors at 
distant sites. Therefore, there continues to be a need to understand what drives 
progression of breast cancer, especially throughout earlier non-invasive stages and from 
non-invasive to invasive stages. Given PCP signalling has a central role in mediating cell 
motility during development; it seems likely that aberrant PCP signalling may play a role 
in progression to an invasive phenotype capable of metastasis. 
Different PCP components have been shown to be involved in modulating cancer 
progression. For example, WNT5A, the prototypical non-canonical Wnt ligand, has been 
shown to promote metastasis of breast cancer by activating Rac and JNK (Pukrop et al. 
2006). WNT5A has also been implicated in metastasis of melanoma and gastric cancer 
(Weeraratna et al. 2002; Kurayoshi et al. 2006). 
25 
 
The Fzd family of receptors, a core component of PCP signalling, consists of 10 
members. One such member, Fzd7, has been shown to act in both canonical and non-
canonical Wnt signalling pathways (Medina et al. 2000). Looking specifically at non-
canonical Wnt signalling, Fzd7-mediated PCP signalling regulates cell movements by 
activating JNK and RHO in Xenopus (Medina et al. 2000; Kinoshita et al. 2003; 
Tanegashima et al. 2008). In humans, Fzd7 promotes invasion through PCP signalling in 
colon cancer cell lines (Vincan et al. 2007; Ueno et al. 2008) and migration in 
hepatocellular carcinoma (Merle et al. 2004). 
There have been three members of Dvl, a cytoplasmic phosphoprotein that acts 
directly downstream of the Fzd receptor, identified in humans (Dvl1, Dvl2, and Dvl3). It 
has been shown that the expression of Dvl1 and Dvl3 is higher in nodal metastases of 
non-small cell lung cancer (NSCLC) compared to primary tumors. Specifically, Dvl1 
expression was correlated with β-catenin expression in metastatic tissues, but there was 
no correlation between Dvl3 and β-catenin expression in primary tumors or metastases. 
Additionally, overexpression of Dvl1 and Dvl3 promoted invasion in A549 and QG56 
lung cancer cell lines but there were differing effects on β-catenin stabilization (Wei et al. 
2008), suggesting that progression of NSCLC to an invasive phenotype may be mediated 
by Dvl1 through the canonical Wnt pathway, but also by Dvl3 independent of β-catenin. 
VANGL1 has been implicated in various cancers. Downregulation of VANGL1 
expression inhibits growth of hepatocellular carcinoma cells (Yagyu et al. 2002). 
VANGL1 has also been shown to bind to the metastasis suppressor Kangai 1/Cluster of 
differentiation 82 (KAI1/CD82) and subsequent overexpression of VANGL1 in the 
mouse colon cancer cell line CT-26 increased invasiveness and adhesion to fibronectin in 
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vitro and increased tumorigenicity and metastasis in vivo (Lee et al. 2004). VANGL1 
overexpression also increased invasion and migration of squamous cancer cells in vitro 
and promoted metastasis in a mouse squamous tumor model in vivo (Lee et al. 2009). 
Additionally, suppression of VANGL1 via small interfering RNA (siRNA) decreased 
colon cancer metastasis in mice, thereby supporting VANGL1’s role as a metastasis 
promoter (Lee et al. 2005). VANGL1 was also implicated in colorectal cancer by 
promoting cell migration and invasion through the formation of a functional complex 
with Dvl and PKCδ (Kho et al. 2009). This suggests that overexpression of VANGL1 can 
promote invasion and metastasis through PCP signalling. Recently, VANGL1 was found 
to form a complex with scribbled homolog (SCRIB) and Nitric oxide synthase 1 
(neuronal) adaptor protein (NOS1AP) along cellular protrusions resembling lamellipodia 
in metastatic breast cancer cells, but not in normal breast cells. Subsequent knockdown of 
VANGL1 with shRNA reduced cell migration, implicating a role for VANGL1 and PCP 
signalling in breast cancer metastasis (Anastas et al. 2012). 
1.4.5 Complex role for PCP signaling in cancer progression 
Despite the large body of evidence that implicates PCP signalling in promoting 
invasion and metastasis, just exactly how PCP signalling is involved in cancer 
progression is still uncertain. Additionally, because of the critical involvement of β-
catenin signalling during tumor development and the antagonism between the different 
Wnt pathways, it is possible that PCP signalling may in some instances/cellular contexts 
inhibit cancer progression (Veeman et al. 2003). 
WNT5A, the prototypical Wnt ligand which activates non-canonical Wnt 
signalling, can act as both an oncogene or tumor suppressor depending on the context.  A  
27 
 
 
 
 
Figure 1.3 Simplified overview of non-canonincal Wnt/PCP signalling. Upstream 
PCP components, such as WNT5A, provide long range signals that establish overall 
polarity within the developing tissue. Core PCP components, such as Fzd, Dishevelled 
(Dvl), Clsr, VANGL1, and Prickle, interpret these long range singles and establish planar 
polarity within single cells. Downstream effectors, such as Daam1, RHO, Rac, ROCK, 
and JNK, use the signals mediated by the upstream and core PCP components to regulate 
cell polarity and migration by acting directly on the cytoskeleton. VANGL1 promotes 
cell migration and invasion through the formation of a functional complex with Dvl and 
PKC. 
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number of studies suggest that WNT5A acts as a tumor suppressor by antagonizing the 
Wnt/β-catenin pathway. For example, disruption of WNT5A expression with a WNT5A 
antisense expression vector mimicked transformation caused by Wnt1 in the mouse 
mammary epithelial cell line C57MG, suggesting that WNT5A is an important regulator 
of cell growth and differentiation (Olson and Gibo 1998). Additionally, there is evidence 
that in hematopoietic malignancies, thyroid carcinoma, colorectal cancer, hepatocellular 
carcinoma, and breast cancer, WNT5A is downregulated and in some cases there is an 
inverse correlation between WNT5A and β-catenin expression (Liang et al. 2003; 
Kremenevskaja et al. 2005; Leris et al. 2005; Ying et al. 2007; Ying et al. 2008; Liu et al. 
2008). As discussed above, however, in more advanced stages of cancer progression, 
WNT5A has been shown to be upregulated and to promote invasion and metastasis in 
melanoma, gastric cancer, and breast cancer (Pukrop et al. 2006; Weeraratna et al. 2002; 
Kurayoshi et al. 2006). Therefore, it appears that the PCP pathway may have a dual role 
in breast cancer progression by behaving as an inhibitor of progression during earlier 
stages and as a promoter of cancer progression during later stages. Thus, it is important to 
fully characterize the PCP pathway to better understand the specific context that allows 
WNT5A to act as either a tumor suppressor or an oncogene. 
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1.5 Thesis rationale and hypothesis 
1.5.1 Rationale 
The 21T cell lines, derived from the same patient with metastatic breast cancer 
(Band et al. 1990), represent a mammary tumor progression series and mimic specific 
stages of breast cancer (21PT, ADH; 21NT, DCIS; 21MT-1, IDC) (Souter et al. 2010). 
Expression profiling of these cell lines has revealed significant differences in the non-
canonical Wnt/PCP pathway members VANGL1 and WNT5A (Souter et al. 2010). 
Specifically, VANGL1 expression is relatively high in the 21NT cell line compared to the 
21PT cell line and remains relatively high in 21MT-1 cells; whereas WNT5A expression 
is moderate in the 21PT cell line, relatively low in the 21NT cell line, and relatively high 
in the 21MT-1 cell line compared to the 21PT and 21NT cell lines (Souter et al. 2010). 
WNT5A has been shown to promote differentiation early in progression. 
However, in later stages it has been shown to promote progression. This dual effect of 
WNT5A may be due to the presence or absence of other Wnt pathway components such 
as VANGL1. Hence, it is important to further characterize the role of this pathway in 
inhibiting or promoting breast cancer progression by addressing whether the cellular 
context (such as VANGL1 expression) can alter the response to WNT5A. 
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1.5.2 Thesis hypothesis 
WNT5A promotes breast cancer progression in the 21T cells in the presence of 
VANGL1. 
1.5.3 Project Objectives 
Objective 1. Improve the in vitro breast cancer progression model to assess 3D 
morphology with the 21T cell lines.  
Objective 2. Test molecular controls of breast cancer progression, specifically the roles 
of WNT5A and VANGL1.  
Specific aim 1: Determine the role of WNT5A overexpression using the 21T cell 
lines via stable transfection. 
Specific aim 2: Determine the role of VANGL1 overexpression using the 21T 
cell lines via stable transfection. 
Specific aim 3: Determine the role of WNT5A and VANGL1 on breast cancer 
progression via shRNA knockdown using the 21T cell lines. 
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Chapter 2  
2 Methods 
2.1 Cell lines and culture conditions 
The 21T parental cell lines (21PT, 21NT, and 21MT-1) were a kind gift from Dr. 
Vimla Band (Dana Farber Cancer Institute, Boston, MA) (Band et al. 1990) and were 
cultured in alpha modification of Eagle’s medium (α-MEM) supplemented with 2mM L-
glutamine, insulin (1mg/mL), epidermal growth factor (12.5ng/mL), hydrocortisone 
(2.8mM), 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1mM 
sodium pyruvate, 0.1mM non-essential amino acids, and 50mg/mL gentamycin reagent 
(now called αHE – all supplements from Wisent Bioproducts, Montreal, QC) as 
previously described (Band et al. 1990). For regular culture conditions, the αHE media 
was further supplemented with 10% fetal bovine serum (FBS; Sigma) and named 
αHE10F. The 21T stable clones were cultured in the above supplemented growth media 
with the addition of 500μg/mL G418 (Wisent Bioproducts) or 0.8μg/mL puromycin 
(Sigma-Aldrich, St. Louis, MO) as selection markers. 
2.2 Generation of WNT5A expression vector 
An expression vector containing WNT5A was constructed in order to overexpress 
Wnt5a protein in 21PT and 21NT cells. To construct the expression vector, WNT5A 
cDNA was PCR-amplified using a pCMV-Sport expression vector containing WNT5A 
(Genbank accession number: NM_003392), provided by the Centre for Applied 
Genomics at The Hospital for Sick Children (University of Toronto, Toronto, ON) as the 
cDNA template. PCR amplification was performed using Phusion High-Fidelity DNA 
Taq Polymerase (New England BioLabs, Pickering, ON) at the following conditions: 
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98
o
C for 30 seconds, followed by 40 cycles of 98
o
C for 7 seconds, 62
o
C for 15 seconds 
and 72
o
C for 45 seconds and finally a 72
o
C hold for 8 minutes.  The primers for PCR 
amplification can be found in Table 2.1. Five separate PCR reactions were completed and 
run on a 1% agarose gel. Bands at the appropriate size (~1500 kb) were gel extracted, 
using an EZ-10 Spin Column DNA Gel Extraction Kit (Bio Basic, Markham, ON) and 
pooled. Next, the WNT5A PCR product was incubated with T4 polynucleotide kinase 
(T4 PNK; New England BioLabs) to phosphorylate the insert. Finally, the WNT5A PCR 
product was purified using a QIAquick PCR purification kit (Qiagen, Mississauga, ON), 
following the manufacturer’s protocol and the concentration was determined by 
spectrophotometry, using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, 
Mississauga, ON).   
 WNT5A was inserted into a pcDNA3.1/myc-His B plasmid (Invitrogen Life 
Technologies, Mississauga, ON), such that the myc-His tag would be fused to the C-
terminus of WNT5A. The plasmid was digested with EcoRV (New England BioLabs) so 
that the WNT5A sequence would be inserted downstream of the pCMV promoter into the 
multiple cloning site. The plasmid was subsequently incubated with calf intestinal 
phosphatase (CIP; New England BioLabs) to dephosphorylate the plasmid. The plasmid 
was then electrophoresed on a 1% agarose gel and extracted using an EZ-10 Spin Column 
DNA Gel Extraction Kit (Bio Basic). 
 The prepared plasmid and WNT5A PCR product were incubated overnight with 
ATP (adenosine triphosphate) and T4 DNA ligase (both from New England BioLabs) at 
16°C to complete the ligation. Competent bacteria (DH5alpha, made in-house) were then 
transformed with the ligated plasmid and streaked on Luria Bertani (LB) agar (Invitrogen 
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Life Technologies) plates with 50µg/mL ampicillin (Gibco Life Technologies, Grand 
Island, NY). Twenty bacteria colonies were picked and expanded in LB + ampicillin 
media, and DNA was isolated using an EZ-10 Spin Column Plasmid DNA Miniprep Kit 
(Bio Basic). The DNA was digested with Xhol and BsrGl (both from New England 
BioLabs) and run on a 1% agarose gel to see which ligation resulted in correct insertion. 
Four of the 20 clones were sent to the DNA Sequencing Facility at Robarts Research 
Institute (London, ON) for sequencing. Clones with the proper sequence were used for 
stable transfections. 
2.3 Site directed mutagenesis 
A pcDNA3.1/myc-His B expression vector containing VANGL1 (previously 
constructed by L. H. Souter and H. S. Leong in a manner similar to WNT5A) underwent 
site directed mutagenesis in order to introduce a stop codon at the end of full length 
VANGL1 (VANGL1-stop) using QuikChange Site-Directed Mutagenesis Kit (Agilent 
Technologies, Wilmington, DE) according to the manufacturer’s protocol. VANGL1-
myc DNA template (50ng), primers designed specially to introduce a stop codon (125ng 
each – see Table 2.1), dNTPs, and PfuTurbo DNA polymerase were mixed in PCR tubes. 
PCR amplification was performed using the following parameters 95
o
C for 30 seconds, 
followed by 18 cycles of 95
o
C for 30 seconds, 55
o
C for 60 seconds, and 68
o
C for 14 
minutes. Five separate PCR reactions were completed. DpnI restriction enzyme was 
added to each amplification reaction for 1 hour at 37°C in order to digest the non-mutated 
parental DNA strand. Competent bacteria (DH5alpha) were then transformed with the 
digested reaction mixture and streaked on LB agar (Invitrogen Life Technologies) plates 
with 50µg/mL ampicillin (Gibco Life Technologies). Twenty bacteria colonies were 
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picked and expanded in LB + ampicillin media, and DNA was isolated using an EZ-10 
Spin Column Plasmid DNA Miniprep Kit (Bio Basic). Clones were sent to the DNA 
Sequencing Facility at Robarts Research Institute for sequencing. Clones with the proper 
sequence were used for stable transfections. 
2.4 Stable transfections 
Stably transfected cell lines were generated to overexpress WNT5A in the 21PT 
and 21NT cells and VANGL1 in the 21PT cells using PolyJet DNA In Vitro Transfection 
Reagent (SignaGen Laboratories, Rockville, MD). Plasmids lacking the gene of interest 
were also transfected into each cell line as an empty vector control. The day before 
transfection, 21PT or 21NT cells were seeded in 10cm dishes at a density that would 
result in 70-80% confluency the next day. Cells were transfected with 5μg of the 
appropriate expression vector following the manufacturer’s protocol. PolyJet/DNA 
complex-containing medium was replaced 18 hours post-transfection with αHE10F. 
Forty-eight hours post-transfection, the media was replaced with αHE10F containing 
500μg/mL G418. Approximately two weeks post-transfection, G418 resistant clones 
were pooled, expanded, and frozen down in vials for later use. 
2.5 Generation of lentivirus particles and transduction 
To generate shRNA containing lentivirus particles against WNT5A, VANGL1, 
and RHOA, HEK293T cells were plated in 2mL of high glucose Dulbecco’s Modified 
Eagle Media (DMEM) + 10% FBS in 6 well plates and incubated for 24 hours prior to 
transfection. Co-transfection of a three plasmid system was carried out using hairpin-
pLKO.1 vector (1ug), envelope plasmid (VSVG/pMD2.G; 100ng) and packaging plasmid 
(pCMV-R8.74psPAX2; 900ng) as previously described (Moffat et al. 2006). SuperFect 
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Transfection Reagent (Qiagen) was used according to the manufacturer’s protocol. Cells 
were incubated for 18 hours post transfection and the media containing the transfection 
reagent was replaced with 2mL high glucose DMEM + 10% FBS. Approximately 48 
hours post-transfection, the viral supernatant (2mL) was collected, passed through a 
0.2μm filter, and stored at 4°C. Media (2mL) was replenished, and viral harvesting was 
repeated a second time 24 hours later, pooled with previous harvest, aliquoted, and stored 
at -80°C until further use. HEK293T cells, pLKO.1-shRNA clones (WNT5A, VANGL1, 
RHOA, LUC – Table 2.2), pMD2.G and pCMV-R8.74psPAX2 plasmids were all gifts 
from Dr. Jason Moffat (University of Toronto). Generation of viral supernatant for 
RHOA and LUC shRNAs were previously prepared by A. E. Robertson and H. S. Leong. 
2.6 Quantitative real-time polymerase chain reaction (qRT-
PCR) 
Total RNA was extracted from 3 biological replicates of each cell line grown in 
10cm dishes using TRIZOL (Invitrogen Life Technologies) following the manufacturer’s 
protocol. RNA concentration was determined using a NanoDrop spectrophotometer 
(Thermo Scientific) (and 5ug of RNA for each sample was DNase I (Invitrogen Life 
Technologies) treated prior to reverse transcription to cDNA using SuperScript III 
Reverse Transcriptase with random hexamers (both from Invitrogen Life Technologies). 
qRT-PCR was performed on cDNA samples and water-primer set only controls using 
RT2 SYBR-Green qPCR Master Mix (SuperArray Biosciences Corporation, Frederick, 
MD). Reactions were carried out in a 96-well plate and were spun for 2500RPM for 30 
seconds prior to placing the plate in the Thermo Cycler. Samples amplified with either 
WNT5A, VANGL1, of RHOA specific primers were reported relative to GAPDH as fold 
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expression normalized to control cell lines. For a list of primers used for qRT-PCR see 
Table 2.1. 
2.7 Preparation of 21T cell lysates 
The 21T cells were grown on 10cm dishes. Subconfluent monolayers were 
washed once with ice cold PBS. RIPA buffer (10nM Tris-HCl pH 7.5, 1mM EDTA, 
0.5mM EGTA, 150nM NaCl, 1% Triton-X 100, 0.5% DOC, and 1% SDS) containing 
one protease inhibitor tablet per 10mL (cOmplete, Mini, EDTA-free Protease Inhibitor 
Cocktail, Roche; Mannheim, Germany) was applied directly to the plate to lyse the cells 
(400uL per 10cm dish). The cells were removed with a cell scraper, collected in a clean 
microcentrifuge tube, and placed on a rotator for 20 minutes at 4°C. Tubes were spun at 
13000 RPM for 10 minutes at 4°C and the resulting supernatant was collected and 
transferred to a clean microcentrifuge tube. The concentrations of the protein samples 
were determined using a BioRad Bradford Assay (Mississauga, ON) by comparing to 
BSA standards. 
2.8 Electrophoresis and Western blotting 
Protein was separated via SDS-PAGE on 8% polyacrylamide gels. Separated 
proteins were transferred onto PVDF membrane and probed for proteins of interest by 
Western blot. Membranes were blocked with 5% skim-milk in TBST (Tris-buffered 
saline with 0.1% Tween-20) overnight at 4°C. After washing membranes once with 
TBST, they were incubated with required primary antibodies for 1.5 hours at room 
temperature. Rat anti-Wnt5a antibody was purchased from R&D Systems (Burlington, 
ON, catalogue no. MAB645) and mouse the anti-myc antibody was a kind gift from Dr. 
Joe Mymryk (London Regional Cancer Program, London, ON). Membranes were washed  
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Table 2.1 Primer sequences for WNT5A cloning, VANGL1 site-directed 
mutagenesis, and qRT-PCR 
 
Primer Name Sequence (5’ to 3’) 
 
WNT5A Cloning Primers 
Forward GCCACCATGAAGAAGTCCATTGGAATATTAA 
Reverse GGAGATCGTGGACCAGTTTGTGTGCAAG 
 
VANGL1 Mutagenesis Primers 
Forward GCTTACAGTCTGAGACATCCGTTTAAATCCAGCACAGTGGCGG 
Reverse CGAGCGGCCGCCACTGTGCTGGATTTAAACGGATGTCTCAGAC 
 
WNT5A qRT-PCR Primers 
Forward GATGCAGATAGGCAGCCGCG 
Reverse GGAGCCCTTGGCGTGGATGC 
  
VANGL1 qRT-PCR Primers 
Forward ACCTGAGTATCCAGCGAGCAG 
Reverse CGCCGTTCATGTTCGGCCTCT 
  
RHOA qRT-PCR Primers 
Forward GGGACACAGCTGGGCAGGAGGA 
Reverse GGTTTCACCGGCTCCTGCTTCA 
  
GAPDH qRT-PCR Primers 
Forward AGGCTGGGGCTCATTTGCAG 
Reverse CCATCCACAGTCTTCTGGGTG 
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Table 2.2 shRNA target sequences used to knockdown WNT5A, VANGL1, RHOA 
and Luciferase 
 
Gene (Identifier) shRNA Target Sequence 
  
RHOA (46) GTTGGGAATAAGAAGGATCTT 
RHOA (48) TGGAAAGACATGCTTGCTCAT 
RHOA (49) GAAAGCAGGTAGAGTTGGCTT 
WNT5A (B1) CAAAGAATGCCAGTATCAATT 
WNT5A (B2) CCAGGTTGTAATTGAAGCCAA 
WNT5A (B3) CCTGTTCAGATGTCAGAAGTA 
VANGL1 (A6) AGTCTGAGACATCCGTTTAAA 
VANGL1 (A8) GCTCTTTATCTCCATGGCATT 
VANGL1 (A10) CTCGTAGTCAATGTGAAGAAA 
Luciferase ACGCTGAGTACTTCGAAATGT 
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with TBST 3 times for 5 minutes each and incubated with horseradish peroxidase (HRP)-
conjugated anti-mouse secondary antibody (Amersham GE Healthcare, catalogue no. 
NXA931 - diluted 1:10000 in 5% skim milk TBST) or HRP-conjugated goat anti-rat 
secondary antibody (R&D Systems catalogue no. HAF005 1:1000 in 5% skim milk 
TBST) for 1 hour at room temperature. Membranes were washed 5 times for 3 minutes 
each. Detection was performed using the ECL Plus Western Blotting Detection Reagents 
(Amersham GE Healthcare, Piscataway, NJ) and then exposed to film in a dark room. 
Densitometric quantification was performed using ImageJ (Open source software, 
National Institutes of Health, USA). 
2.9 Three-dimensional Matrigel culture and 
immunofluorescence 
Subconfluent monolayers were trypsinized, washed, resuspended in αHE media 
containing 2% growth factor reduced Matrigel (BD Biosciences, Mississauga, ON) and 
2% FBS, and plated as single cell suspensions on 100% Matrigel in 8-well chambers 
slides as previously described (Debnath et al. 2003; Lee et al. 2007). αHE media 
containing 2% Matrigel and 2% FBS was changed every 3 days. Following the indicated 
time points, the cell colonies were fixed with 10% (w/v) formalin in phosphate buffered 
saline (PBS) for 20 minutes at room temperature. Cells were then permeabilized with 
0.5% Triton X-100 in PBS for 20 minutes at 4°C and blocked with 10% normal goat 
serum (Invitrogen Life Technologies) for 45 minutes at room temperature. Cell colonies 
were probed using a purified mouse anti-E-cadherin primary antibody (BD Biosciences, 
catalogue no. 61081) for 1.5 hours in 10% normal goat serum at room temperature. 
Following primary antibody incubation, the cell colonies were washed 3 times with PBS 
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for 5 minutes per wash. Cell colonies were then probed with Alexa Fluor 488 Goat anti-
mouse secondary antibody (Invitrogen Life Technologies) and Alexa Fluor 546 
conjugated phalloidin (Invitrogen Life Technologies) to stain for F-actin in 10% normal 
goat serum for 1 hour at room temperature. Following secondary antibody and phalloidin 
incubation, the cell colonies were washed 5 times with PBS for 3 minutes each. Finally, 
cell colonies were incubated for 15 minutes at room temperature with 3μg/mL Hoechst 
33342, trihydrochloride, trihydrate (Invitrogen Life Technologies) to stain for the nuclei. 
Chamber slide gaskets were removed prior to mounting with Vectashield mounting 
medium (Vector Laboratories, Burlington, ON). Images were captured with an Olympus 
Confocal Imaging System (FluoView FV1000 coupled to the IX81 Motorized Inverted 
System Microscope) at the Victoria Research Laboratory Confocal Microscope Core 
Facility (London, ON) and processed using Volocity software (PerkinElmer, 
Woodbridge, ON). 
2.10 Transwell migration assay 
The migration of the 21PT and 21NT cells overexpressing WNT5A was tested 
using a Boyden chamber system (Corning Life Sciences; Lowell, MA). The day before 
the assay, 6.5mm transwell inserts (8.0μm pores) were each coated with 6μg of gelatin 
(diluted in 60μL of sterile Milli-Q water). Plates were allowed to dry overnight at room 
temperature. On the day of the assay, the gelatin coated transwell inserts were 
reconstituted by adding 0.1mL of αHE media supplemented with 0.1% BSA to the upper 
chamber for 90 minutes at room temperature. Subconfluent cells were washed twice with 
PBS, and resuspended in serum free media containing 0.1% BSA at a concentration of 
5x10
5
 cells/mL. Media containing chemoattractant (0.8mL of αHE10F) was added to the 
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bottom chambers and 0.1mL of the cell suspension (5.0x10
4
 cells per well) was 
immediately added to the upper chambers in triplicate. The Boyden chambers were 
incubated at 37°C and 5% CO2 for 5 hours. During recombinant Wnt5a treatment, 
recombinant Wnt5a (R&D Systems) was added at the upper and lower chambers at the 
beginning of the assay. 
After the assay was complete, the inner chamber inserts were removed and 
fixed/stained/washed using the Diff-Quick staining system (modified Wright Giemsa 
stain, Sigma-Aldrich) according to manufacturer’s protocol. The cells that did not 
migrate to the underside of the membrane were removed using a cotton swab. The insert 
wells were allowed to dry overnight and images of 5 non-overlapping fields of view were 
acquired using Image-Pro Analysis Software (Media Cybernetics, Acton, MA) coupled to 
an inverted microscope. Images were captured at 10X objective. Cells were counted from 
these pictures using ImageJ (Open source software). 
2.11 Transwell invasion assay 
The invasion of the 21PT and 21NT cells overexpressing WNT5A and VANGL1 
was tested using a Boyden chamber system precoated with Matrigel (reconstituted 
basement membrane proteins - BD Biosciences). Two hours prior to plating, the Matrigel 
precoated transwells (6.5mm inserts and 8.0μm pores) were reconstituted by adding 
0.5mL of αHE media supplemented with 0.1% BSA to the upper and lower chambers at 
37°C and 5% CO2. Cells were washed twice with PBS, and resuspended in serum free 
media containing 0.1% BSA at a concentration of 1x10
5
 cells/mL. The media used for 
reconstitution of the Matrigel in the lower and upper chambers was removed. Media 
containing chemoattractant (0.75mL of αHE10F) was added to the bottom chambers and 
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0.5mL of the cell suspension (5x10
4
 cells) was immediately added to the upper chambers 
in triplicate. The Boyden chambers were incubated at 37°C and 5% CO2 for 22 hours. 
During recombinant Wnt5a treatment, recombinant Wnt5a (R&D Systems) was added at 
the appropriate concentration to the upper and lower chambers at the beginning of the 
assay. 
After the assay was complete, the inner chamber inserts were removed and 
fixed/stained/washed using the Diff-Quick staining system (Sigma-Aldrich) according to 
manufacturer’s protocol. The cells that did not invade to the underside of the membrane 
were removed using a cotton swab. The insert wells were allowed to dry overnight and 
images of 5 non-overlapping fields of view were acquired using Image-Pro Analysis 
Software (Media Cybernetics) coupled to an inverted microscope. Images were captured 
at 10X objective. Cells were counted from these pictures using ImageJ (Open source 
software). 
2.12 Statistical analysis 
Statistical analyses were done using GraphPad Prism 5.0 software (La Jolla, CA). 
Colony morphology experiments, migration and invasion assays, and mRNA and protein 
levels were analyzed using ANOVA followed by Tukey’s post hoc test (for comparison 
between more than two groups) or Student’s t-test (for comparison between two groups). 
P-values less than 0.05 were considered statistically significant. 
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Chapter 3  
3 Results 
3.1 Objective 1: Improve the in vitro breast cancer 
progression model to assess 3D morphology with the 
21T cell lines 
The use of the 21T cell lines in a 3D in vitro system has proven useful in 
identifying potential regulators of progression (Souter et al. 2010); however, the method 
of embedding the 21T cell lines in Matrigel in order to assess 3D morphology is costly, 
time consuming, and the thickness of the Matrigel layer does not allow for easy 
visualization of the embedded cells in situ. Here, the 21T cell lines were characterized 
using a modified 3D in vitro system in which cells are seeded on top of Matrigel, as 
opposed to embedded within (Lee et al. 2007; Debnath et al. 2003), and 3D morphology 
was analyzed using confocal microscopy. First, each parental cell line was characterized 
over time (section 3.1.1 to 3.1.3) and finally, all three cell lines were compared in order 
to choose a suitable endpoint to the 3D morphology assay (section 3.1.4). 
3.1.1 Characterization of the 21PT (ADH) cell line 
In order to characterize the 21PT cell line, cells were grown on top of 100% 
Matrigel in a 2% FBS, 2% Matrigel solution for 3, 6, 9, and 12 days; after the specified 
time point the cells were fixed, permeabilized, stained, and imaged using a confocal 
microscope. The percentage of 21PT colonies (a group of 2 or more cells) that exhibited 
lumen formation at day 3 was 7.19% (SE 2.34), at day 6 was 20.35% (SE 5.30), at day 9 
was 47.49% (SE 2.20), and at day 12 was 57.88% (SE 2.59) (Figure 3.1A, 3.1B). These 
differences were significant between day 3 and day 9 (p<0.001), day 3 and day 12 
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(p<0.001), day 6 and day 9 (p<0.01), and day 6 and day 12 (p<0.001). The percentage of 
21PT colonies that were polarized (unequal distribution of actin and E-cadherin) at day 3 
was 43.35% (SE 5.26), at day 6 was 56.85% (SE 4.17), at day 9 was 62.69% (SE 3.67), 
and at day 12 was 69.28% (SE 2.33) (Figure 3.1A, 3.1B). These differences were 
significant between day 3 and day 9 (p<0.05) and day 3 and day 12 (p<0.01). In the 
colonies that were considered polarized, actin was localized to the apical region of the 
colony (inside the colony located near the lumen) and E-cadherin was localized to the cell 
to cell junctions and the basal region of the colony. The percentage of 21PT colonies that 
were spherical (round, smooth edged colony) vs. non-spherical at day 3 was 39.60% (SE 
9.93), at day 6 was 66.99% (SE 4.24), at day 9 was 72.41% (SE 5.68), and at day 12 was 
71.45% (SE 0.51) (Figure 3.1A, 3.1B). These differences were significant between day 3 
and day 9 (p<0.05) and day 3 and day 12 (p<0.05). The number of nuclei per colony in 
the 21PT cell line at day 3 was 3.25 (SE 0.53), at day 6 it was 6.96 (SE 0.50), at day 9 it 
was 8.09 (SE 0.74), and at day 12 it was 12.92 (SE 1.65) (Figure 3.1C).  
3.1.2 Characterization of the 21NT (DCIS) cell line 
In order to characterize the 21NT cell line, cells were grown on top of 100% 
Matrigel in a 2% FBS, 2% Matrigel solution for 3, 6, 9, and 12 days; after the specified 
time point cells were fixed, permeabilized, stained, and imaged using a confocal 
microscope. The percentage of 21NT colonies that exhibited lumen formation at day 3 
was 9.56% (SE 0.89), at day 6 was 15.37% (SE 0.65), at day 9 was 13.48% (SE 2.40), 
and at day 12 was 29.21% (SE 5.29) (Figure 3.2A, 3.2B). These differences were 
significant between day 3 and day 12 (p<0.01), day 6 and day 12 (p<0.05), and day 9 and 
day 12 (p<0.01). The percentage of 21NT colonies that were polarized at day 3 was  
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Figure 3.1 Characterization of the 21PT cell line grown in 3D Matrigel. The 21PT 
cells were grown on top of 100% Matrigel in αHE + 2% FBS and 2% Matrigel for 3, 6, 9, 
and 12 days. Cell colonies were fixed, permeabilized, stained, and imaged using confocal 
microscopy. A) Representative cell colonies are shown at each day. Actin is shown in 
red, E-cadherin is shown in green, and the nuclear stain Hoechst is shown in blue. An 
overlay of all three channels is shown in the final set of panels. B) The proportion of 
colonies exhibiting lumen formation is increased from day 3 to day 9, from day 3 to day 
12, from day 6 to day 9, and from day 6 to day 12. The proportion of polarized colonies is 
increased from day 3 to day 6 and from day 3 to day 12. The proportion of spherical 
colonies (vs. non-spherical colonies) is increased from day 3 to day 9 and from day 3 to 
day 12. C) The number of nuclei per colony increased over time. Colony morphology 
was analyzed using one-way ANOVA followed by Tukey’s post hoc test. * p<0.05, ** 
p< 0.01, *** p<0.001. Scale bar represent 30μm. 
46 
 
54.59% (SE 11.31), at day 6 was 49.06% (SE 3.77), at day 9 was 38.25% (SE 3.10), and 
at day 12 was 45.94% (SE 8.78) (Figure 3.2A, 3.2B). These differences were not 
significant. In the colonies that were considered polarized, actin was localized to the 
center of the colony (inside the colony, apical aspect of the cells) and E-cadherin was 
localized to the cell to cell junctions. The percentage of 21NT colonies that were 
spherical (vs. non-spherical) at day 3 was 51.14% (SE 2.59), at day 6 was 61.10% (SE 
2.81), at day 9 was 44.12% (SE 4.80), and at day 12 was 50.99% (SE 3.10) (Figure 3.2A, 
3.2B). These differences were not significant. The number of nuclei per colony in the 
21NT cell line at day 3 was 6.44 (SE 0.93), at day 6 it was 12.42 (SE 1.38), at day 9 it 
was 20.00 (SE 2.95), and at day 12 it was 29.25 (SE 5.82) (Figure 3.2C). 
3.1.3 Characterization of the 21MT-1 (IDC) cell line 
In order to characterize the 21MT-1 cell line, cells were grown on top of 100% 
Matrigel in a 2% FBS, 2% Matrigel solution for 3, 6, 9, and 12 days; after the specified 
time point cells were fixed, permeabilized, stained, and imaged using a confocal 
microscope. The percentage of 21MT-1 colonies that exhibited lumen formation at day 3 
was 0% (SE 0), at day 6 was 0.89% (SE 0.45), at day 9 was 4.78% (SE 1.75), and at day 
12 was 1.67% (SE 0.67) (Figure 3.3A, 3.3B). These differences were not significant. The 
percentage of 21MT-1 colonies that were polarized at day 3 was 12.80% (SE 1.26), at 
day 6 was 16.31% (SE 7.38), at day 9 was 19.96% (SE 1.78), and at day 12 was 6.67% 
(SE 5.44) (Figure 3.3A, 3.3B). These differences were not significant. Actin was 
localized to the cell periphery (not apically oriented) and E-cadherin was localized to the 
cytoplasmic region of cell (not to the cell to cell junctions). The percentage of 21MT-1 
colonies that were spherical (vs. non-spherical) at day 3 was 4.91% (SE 0.22), at day 6  
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Figure 3.2 Characterization of the 21NT cell line grown in 3D Matrigel. The 21NT 
cells were grown on top of 100% Matrigel in αHE + 2% FBS and 2% Matrigel for 3, 6, 9, 
and 12 days. Cell colonies were fixed, permeabilized, stained, and imaged using confocal 
microscopy. A) Representative cell colonies are shown at each day. Actin is shown in 
red, E-cadherin is shown in green, and the nuclear stain Hoechst is shown in blue. An 
overlay of all three channels is shown in the final set of panels. B) The proportion of 
colonies exhibiting lumen formation is increased from day 3 to day 12, from day 6 to day 
12, and from day 9 to day 12. The proportion of polarized colonies and spherical colonies 
is not different among the days. C) The number of nuclei per colony increased over time. 
Colony morphology was analyzed using one-way ANOVA followed by Tukey’s post hoc 
test. * p<0.05, ** p< 0.01. Scale bar represent 30μm. 
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was 6.67% (SE 4.04), at day 9 was 15.61% (SE 2.57), and at day 12 was 17.08% (SE 
3.06) (Figure 3.3A, 3.3B). These differences were not significant. The number of nuclei 
per colony in the 21MT-1 cell line at day 3 was 4.69 (SE 0.42), at day 6 it was 11.39 (SE 
1.52), at day 9 it was 27.06 (SE 4.20), and at day 12 it was 56.17 (SE 9.86) (Figure 
3.3C). 
3.1.4 Comparison of each 21T cell line and selecting a suitable 
endpoint 
In order to choose a suitable endpoint for the 3D morphology assay data from 
sections 3.1.1 to 3.1.3 were reanalyzed with respect to each cell line instead of time. At 
day 9 (data not shown) and day 12 (Figure 3.4A, 3.4B) each cell line displayed a 
characteristic morphology with respect to lumen formation, polarized colonies, and 
spherical colonies. Between the three cell lines, there was an overall decrease in lumen 
formation, polarized colonies, and spherical colonies from 21PT to 21NT to 21MT-1. 
There was also an increase in the number of nuclei per cell colony from 21PT to 21NT to 
21MT-1 (Figure 3.4C). Thus, using the 21T cells in an on-top Matrigel assay to measure 
3D morphology yielded comparable results to the embedded method that was previously 
used in our lab (Souter et al. 2010), but in a quicker, more efficient fashion. 
3.2 Objective 2: Test molecular controls of breast cancer 
progression. Specific aim 1: Determine the role of 
WNT5A overexpression using the 21T cells lines via 
stable transfection 
WNT5A expression was found to be moderate in 21PT (ADH), low in 21NT 
(DCIS), and high in 21MT-1 (IDC) (Souter et al. 2010). To determine the functional role  
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Figure 3.3 Characterization of the 21MT-1 cell line grown in 3D Matrigel. The 
21MT cells were grown on top of 100% Matrigel in αHE + 2% FBS and 2% Matrigel for 
3, 6, 9, and 12 days. Cell colonies were fixed, permeabilized, stained, and imaged using 
confocal microscopy. A) Representative cell colonies are shown at each day. Actin is 
shown in red, E-cadherin is shown in green, and the nuclear stain Hoechst is shown in 
blue. An overlay of all three channels is shown in the final set of panels. B) The 
proportion of colonies exhibiting lumen formation, polarization, and sphericalness did not 
change between any of the days. C) The number of nuclei per colony increased over time. 
Colony morphology was analyzed using a one-way ANOVA followed by Tukey’s post 
hoc test and p<0.05 was considered significant. Scale bar represent 30μm. 
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Figure 3.4 21T cell lines form distinct growth patterns in 3D Matrigel after 12 days. 
The 21MT cells were grown on top of 100% Matrigel in αHE + 2% FBS and 2% 
Matrigel for 12 days. Cell colonies were fixed, permeabilized, stained, and imaged using 
confocal microscopy. A) Representative cell colonies are shown at each day. Actin is 
shown in red; E-cadherin is shown in green; and the nuclear stain Hoechst is shown in 
blue. An overlay of all three channels is shown in the final set of panels. B) The 
proportion of colonies exhibiting lumen formation decreased from 21PT to 21NT to 
21MT-1, the proportion of polarized colonies decreased from 21NT to 21MT-1, and the 
proportion of spherical colonies (vs. non-spherical colonies) decreased from 21PT to 
21NT to 21MT-1. C) The number of nuclei per colony increased from 21PT to 21NT to 
21MT-1. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc 
test and p<0.05 was considered statistically significant. *p<0.05, ** p<0.01, *** 
p<0.001. Scale bar represent 30μm. 
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of WNT5A in the transition between different stages of breast cancer progression, 
WNT5A was overexpressed in 21PT and 21NT cells. The 3D morphology and invasive 
potential of these cell lines were examined. 
3.2.1 WNT5A is differentially expressed in the 21T cell lines 
WNT5A expression was examined at the mRNA and protein levels in the 21T cell 
lines. Total RNA was extracted from the 21PT, 21NT and 21MT-1 cell lines and 
subsequently reverse transcribed into cDNA. Primers specific to WNT5A were used in a 
qRT-PCR to examine relative levels of WNT5A among the three cell lines. WNT5A 
mRNA expression is higher in the 21MT-1 cell line compared to both the 21PT and 
21NT cell lines by 43.7-fold (p<0.01) and 109.1-fold (p<0.01) respectively; however, 
WNT5A mRNA levels were not significantly different between the 21PT and 21NT 
parental cell lines (Figure 3.5A). Protein was extracted from the 21T parental cell lines 
and analyzed by Western blot with an antibody specific to Wnt5a protein. Wnt5a 
expression was higher in the 21MT-1 cell line compared to the 21PT and 21NT cell lines. 
Wnt5a expression levels were higher in the 21MT-1 cell line compared to the 21PT and 
21NT cell line by 5.02-fold (p<0.01) and 3.78-fold (p<0.01) respectively; however, the 
difference between the expression levels of Wnt5a between 21PT and 21NT was not 
significant (Figure 3.5B, 3.5C). 
3.2.2 WNT5A expression is increased in 21PT and 21NT cells after 
transfection 
A WNT5A expression vector containing a myc-His epitope was constructed and 
transfected into 21PT cells (21PT + WNT5A) and 21NT cells (21NT + WNT5A). The 
expression vector alone (without WNT5A) was also transfected into 21PT cells (21PT +  
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Figure 3.5 WNT5A mRNA and protein levels in the 21T parental cell lines. For ease 
of comparison, the expression levels for 21PT parental cells were set to 1. A) WNT5A 
mRNA expression is higher in the 21MT-1 cell line compared to both the 21PT and 
21NT cell lines.WNT5A expression was similar in both 21PT and 21NT parental cell 
lines. mRNA expression levels were calculated as a ratio to the housekeeping gene 
GAPDH. B, C) Wnt5a protein expression was higher in the 21MT-1 cell line compared to 
the 21PT and 21NT cell. Wnt5a protein levels were similar in both 21PT and 21NT 
parental cell lines. Protein levels were calculated as a ratio with β-actin. An ANOVA was 
performed with Tukey’s post hoc test and p<0.05 was considered statistically significant. 
**p<0.01. 
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EV) and 21NT cells (21NT + EV). Both qRT-PCR and Western blot were used to 
determine if levels of WNT5A were increased in 21PT + WNT5A cells and 21NT + 
WNT5A cells compared to empty vector controls.  
WNT5A mRNA was increased in both the 21PT + WNT5A cells and 21NT + 
WNT5A cells compared to their respective empty vector controls. WNT5A mRNA was 
increased in the 21PT + WNT5A cell line by 675-fold compared to 21PT + EV 
(p<0.001). WNT5A mRNA was increased in the 21NT + WNT5A cell line by 272-fold 
compared to the 21NT + EV cell line (p<0.001) (Figure 3.6A, 3.6B). Likewise, Wnt5a 
protein was increased in both the 21PT + WNT5A cells and 21NT + WNT5A cells 
compared to their respective empty vector controls. In the 21PT + WNT5A cell line, 
Wnt5a protein was increased 6.02-fold compared to the 21PT + EV cells (p<0.001). In 
the 21NT + WNT5A cell line, Wnt5a protein was increased 6.67-fold compared to the 
21NT + EV cells (p<0.001) (Figure 3.6E, 3.6F, 3.6G). In order to show that the increase 
in Wnt5a was due to transfection of a WNT5A-myc construct, an anti-myc antibody was 
used to detect myc epitope expression. The 21PT + WNT5A and 21NT + WNT5A cell 
lines had myc positivity shown by Western blot at the predicted molecular weight of 
Wnt5a-myc (Figure 3.6C, 3.6D). 
3.2.3 WNT5A overexpression increased migration of both 21PT and 
21NT cells 
To first assess the migratory ability of WNT5A overexpression in the 21T cell 
lines, the 21PT + WNT5A and 21NT + WNT5A cells were used in a transwell migration 
assay. 21PT + EV, 21PT + WNT5A, 21NT + EV and 21NT + WNT5A cells were placed 
in the upper chamber of a transwell migration system (membranes with 8.0μm pores 
coated with 6μg of gelatin) and allowed to migrate through the pores in order to reach  
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Figure 3.6 WNT5A mRNA and protein levels in the 21T cell lines after transfection 
with WNT5A-myc. For ease of comparison, the expression levels for 21PT parental cells 
were set to 1. A, B) WNT5A mRNA expression is increased in the 21PT + WNT5A and 
21NT + WNT5A cell lines compared to the respective empty vector controls. mRNA 
expression levels were calculated as a ratio to the housekeeping gene GAPDH. C, D) 
Both 21PT + WNT5A and 21NT + WNT5A cell lines are positive for myc protein 
expression at the predicted molecular weight for a Wnt5a-myc fusion protein. E, F, G) 
Wnt5a protein expression was increased in the 21PT + WNT5A and the 21NT + WNT5A 
cell lines compared to the respective empty vector controls. Protein levels were 
calculated as a ratio to β-actin. To analyze mRNA and protein levels a Student’s t-test 
was performed and p<0.05 was considered statistically significant. **p<0.01, 
***p<0.001. 
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FBS (chemoattractant) that was present in the lower chamber. WNT5A overexpression  
increased migration in both 21PT and 21NT cell lines. WNT5A overexpression increased 
the 21PT cell’s ability to migrate from 24.67 (SE 11.84) cells per field of view for the 
21PT + EV cell line to 71.00 (SE 2.66) cells per field of view for the 21PT + WNT5A 
cell line (p<0.01) (Figure 3.7A, 3.7B). WNT5A overexpression increased the 21NT cells’ 
ability to migrate from 18.47 (SE 0.267) cells per field of view for the 21NT + EV cell 
line to 147.8 (SE 4.40) cells per field of view for the 21NT + WNT5A cell line (p<0.001) 
(Figure 3.7A, 3.7B). 
3.2.4 WNT5A overexpression increased invasion of 21NT cells but 
not of 21PT cells 
To assess the invasive ability of WNT5A overexpression in the 21T cell lines, the 
21PT + WNT5A and 21NT + WNT5A cells were used in a transwell invasion assay. 
21PT + EV, 21PT + WNT5A, 21NT + EV and 21NT + WNT5A cells were placed in the 
upper chamber of a transwell system (membranes with 8.0μm pores precoated with 
Matrigel) and allowed to invade through the pores in order to reach FBS 
(chemoattractant) that was present in the lower chamber. WNT5A overexpression 
increased invasion in 21NT cell line only. WNT5A overexpression increased the 21NT 
cell’s ability to invade from 31.67 (SE 4.04) cells per field of view in the 21NT + EV cell 
line to 104.7 (SE 20.13) cells per field of view in the 21NT + WNT5A (p<0.01) cell line 
(Figure 3.8A, 3.8B). 
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Figure 3.7 WNT5A overexpression increased migration of 21PT and 21NT cells. A) 
Transwell migration assay using 21PT + EV, 21PT + WNT5A, 21NT + EV, and 21NT + 
WNT5A cells towards FBS for 5 hours. 21PT + WNT5A cells showed an increase in the 
number of cell the migrated to the underside of the transwell membranes compared to the 
empty vector control. Likewise, 21NT + WNT5A cells exhibited an increase in the 
number of cells that migrated to the underside of the transwell membrane compared to 
the empty vector control. B) Representative images used for counting the number of cells 
per field of view. To analyze migration a one-way ANOVA was performed with Tukey’s 
post hoc test and p<0.05 was considered statistically significant. **p<0.01, ***p<0.001. 
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Figure 3.8 WNT5A overexpression increased invasion of 21NT cells but not of 21PT 
cells. A) Transwell invasion assay using 21PT + EV, 21PT + WNT5A, 21NT + EV, and 
21NT + WNT5A cells towards FBS for 20 hours. 21NT + WNT5A cells showed an 
increase in the number of cells that invaded to the underside of the transwell membrane 
compared to the empty vector control. However, WNT5A overexpression did not 
increase invasion of 21PT cells. B) Representative images used for counting the number 
of cells per field of view. To analyze invasion a one-way ANOVA was performed with 
Tukey’s post hoc test and p<0.05 was considered statistically significant. **p<0.01, 
***p<0.001. 
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3.2.5 WNT5A overexpression decreased the percentage of spherical 
colonies formed by 21NT cells but had no effect on 3D 
morphology of 21PT cells 
The 3D morphology of the 21PT and 21NT transfectants was assessed using the 
modified 3D morphology assay described in Section 3.1. The 21PT + EV, 21PT + 
WNT5A, 21NT + EV, and 21NT + WNT5A were grown on top of 100% Matrigel in a 
αHE media containing 2% Matrigel and 2% FBS for 12 days. WNT5A overexpression 
had no effect on 3D morphology with respect to lumen formation and polarized colonies 
in either cell line. However, WNT5A overexpression decreased the percentage of 
colonies that were spherical in 21NT cells only. The percentage of spherical colonies 
decreased from 37.37% (SE 5.00) in 21NT + EV cells to 22.26% (SE 1.46) in 21NT + 
WNT5A cells (p<0.05) (Figure 3.9A, 3.9B). There was no effect on the number of nuclei 
per cell colony after WNT5A overexpression (Figure 3.9C). 
3.2.6 WNT5A overexpression increased total RHOA expression and 
shRNA targeting RHOA reduced its expression in 21PT cells 
To investigate the functional response of WNT5A overexpression in 21PT cells, 
the downstream effector RHOA was examined. Overexpression of WNT5A in 21PT cells 
increased the expression of RHOA at the mRNA level. RHOA expression was increased 
by 1.75-fold (p<0.01) (Figure 3.10). To determine if WNT5A-induced RHOA expression 
plays a functional role in 21PT cell migration or invasion, RHOA expression was 
knocked down using a panel of three short hairpin RNAs (Table 2.2). RHOA mRNA 
knockdown was achieved for one of the three shRNAs in 21PT + WNT5A cells. RHOA 
expression was decreased to a level similar to 21PT + EV cells, compared to an off target 
knockdown control (21PT + WNT5A + Luciferase shRNA) (Figure 3.10). 
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Figure 3.9 WNT5A overexpression decreased the proportion of spherical colonies 
formed by 21NT cells and had no effect on colony morphology of 21PT cells. The 
21PT + EV, 21PT + WNT5A, 21NT + EV, and 21NT + WNT5A cells were grown on top 
of 100% Matrigel in a αHE + 2% FBS and 2% Matrigel 12 days. Cell colonies were 
fixed, permeabilized, stained, and imaged using confocal microscopy. A) Representative 
cell colonies are shown at each day. Actin is shown in red, E-cadherin is shown in green, 
and the nuclear stain Hoechst is shown in blue. An overlay of all three channels is shown 
in the final set of panels. B) There was a decrease in the proportion of spherical colonies 
formed by 21NT cells when overexpressing WNT5A. C) WNT5A overexpression had no 
effect on the number of nuclei per cell colony. Data regarding colony morphology and 
nuclei were analyzed using one-way ANOVA followed by Tukey’s post hoc test and 
p<0.05 was considered statistically significant. *p<0.05. Scale bar represents 30μm. 
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Figure 3.10 WNT5A overexpression increases total RHOA expression and shRNA 
targeting RHOA reduces its expression in the 21PT cell line. After overexpression of 
WNT5A in the 21PT cell line that was an increase in the expression of total RHOA at the 
mRNA level. RHOA expression was knocked down using a panel of three shRNAs. 
RHOA mRNA knockdown was achieved in one of the three shRNAs in the 21PT + 
WNT5A cell line to a level similar to 21PT + EV compared to an off target knockdown 
control (21PT + WNT5A + Luciferase shRNA). mRNA expression was analyzed using 
one-way ANOVA followed by Tukey’s post hoc test and p<0.05 was considered 
statistically significant. **p<0.01. 
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3.2.7 RHOA knockdown reduced WNT5A-induced migration but had 
no effect on invasion of 21PT cells 
To assess the change in migration due to RHOA knockdown in 21PT + WNT5A 
cells, transwell migration assays were used. 21PT + EV, 21PT + WNT5A + shRHOA, 
and 21PT + WNT5A + shLUC cells were placed in the upper chamber of a transwell 
migration system and allowed to migrate through the pores in order to reach FBS 
(chemoattractant) that was present in the lower chamber. RHOA knockdown decreased 
migration of 21PT + WNT5A cells from 59.33 (SE 9.53) cells per field of view to 15.00 
(SE 0.58) cells per field of view (p<0.01), a level similar to that of 21PT + EV (Figure 
3.11A, 3.11C). To assess the change in invasion due to RHOA knockdown in 21PT + 
WNT5A cells, transwell invasion assays were again used. 21PT + EV, 21PT + WNT5A + 
shRHOA, and 21PT + WNT5A + shLUC cells were placed in the upper chamber of the 
transwell invasion system (membranes precoated with Matrigel) and allowed to invade 
through the pores in order to reach FBS (chemoattractant) that was present in the lower 
chamber. There was no difference in invasion between these three cell lines (Figure 
3.11B, 3.11C). 
3.2.8 WNT5A overexpression increased RHOA expression and 
shRNA targeting RHOA reduced its expression in 21NT cells 
To similarly investigate the functional response to WNT5A overexpression in 
21NT cells, the downstream effector RHOA was again examined in these cells. 
Overexpression of WNT5A in the 21NT cell line increased the expression of RHOA at 
the mRNA level by 1.77-fold (p<0.01) (Figure 3.12). To determine if WNT5A induced 
RHOA expression plays a functional role in 21NT cell migration or invasion, RHOA 
expression was knocked down using the same panel of three short hairpin RNAs used in  
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Figure 3.11 RHOA knockdown reduced the WNT5A induced increase in migration 
but had no effect on invasion of 21PT cells. A) Transwell migration assay using 21PT 
+ EV, 21PT + WNT5A + shLUC, and 21PT + WNT5A + shRHOA cells towards FBS for 
5 hours. Knockdown of RHOA in 21PT + WNT5A cells decreased migration to levels 
similar to 21PT + EV. Such an effect was not seen using an off target knockdown. B) 
Transwell invasion assay using 21PT + EV, 21PT + WNT5A + shLUC, and 21PT + 
WNT5A + shRHOA cells towards FBS for 20 hours. Knockdown of RHOA in 21PT + 
WNT5A cells had no effect on invasion. C) Representative images used for counting the 
number of cells per field of view. To analyze the number of cells per field of view a one-
way ANOVA was performed with Tukey’s post hoc test and p<0.05 was considered 
statistically significant. **p<0.01. 
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21PT cells (Table 2.2). RHOA mRNA knockdown was achieved using two of the three 
shRNAs in 21NT + WNT5A cells. In the most effective knockdown, RHOA expression 
was decreased to a level lower than the 21NT + EV compared to an off target knockdown 
control (21NT + WNT5A + Luciferase shRNA) (Figure 3.12). 
3.2.9 RHOA knockdown reduced WNT5A-induced migration and 
invasion of 21NT cells 
To assess the change in migration due to RHOA knockdown in 21NT cells 
overexpressing WNT5A, transwell migration assays were used.  21NT + EV, 21NT + 
WNT5A + shRHOA, and 21NT + WNT5A + shLUC cells were placed in the upper 
chamber of a transwell migration system and allowed to migrate through the pores in 
order to reach FBS (chemoattractant) that was present in the lower chamber. RHOA 
knockdown decreased migration of 21NT + WNT5A cells from 240.0 (SE 41.63) cells 
per field of view to 106.7 (SE 6.88) cells per field of view (p<0.05), a level similar to 
21NT + EV (Figure 3.13A, 3.13C). To assess the change in invasion due to RHOA 
knockdown in 21NT cells overexpressing WNT5A, transwell invasion assays were again 
used. 21NT + EV, 21NT + WNT5A + shRHOA, and 21NT + WNT5A + shLUC cells 
were placed in the upper chamber of a transwell invasion system and allowed to invade 
through the pores in order to reach FBS (chemoattractant) that was present in the lower 
chamber. RHOA knockdown decreased invasion of 21NT + WNT5A cells from 152.7 
(SE 9.49) cells per field of view to 102.3 (SE 13.68) cells per field of view (p<0.05), to a 
level that was still higher than 21NT + EV (p<0.01) (Figure 3.13B, 3.13C). 
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Figure 3.12 WNT5A overexpression increased RHOA expression and shRNA 
targeting RHOA reduced its expression in 21NT cells. After overexpression of 
WNT5A in 21NT cells there was an increase in the expression of RHOA at the mRNA 
level. RHOA expression was knocked down using a panel of three shRNAs. RHOA 
mRNA knockdown was achieved in 21NT + WNT5A cells using two of the three 
shRNAs to a level similar to or less than 21NT + EV. No significant effect was seen 
using an off target knockdown control (21NT + WNT5A + Luciferase shRNA). mRNA 
expression was analyzed using one-way ANOVA followed by Tukey’s post hoc test and 
p<0.05 was considered statistically significant. **p<0.01, ***p<0.001. 
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Figure 3.13 RHOA knockdown reduced the WNT5A-induced increase in migration 
and partially reduced WNT5A-induced invasion of 21NT cells. A) Transwell 
migration assay using 21NT + EV, 21NT + WNT5A + shLUC, and 21NT + WNT5A + 
shRHOA cells towards FBS for 5 hours. Knockdown of RHOA in 21NT + WNT5A cells 
decreased migration to a level similar to 21NT + EV. In contrast, no significant effect 
was seen using the off target knockdown control. B) Transwell invasion assay using 
21NT + EV, 21NT + WNT5A + shLUC, and 21NT + WNT5A + shRHOA cells towards 
FBS for 20 hours. Knockdown of RHOA in 21NT + WNT5A cells partially decreased 
WNT5A-induced invasion, whereas no significant effect was seen using the off target 
knockdown control. C) Representative images used for counting the number of cells per 
field of view. To analyze the number of cells per field of view a one-way ANOVA was 
performed with Tukey’s post hoc test and p<0.05 was considered statistically significant. 
*p<0.05, **p<0.01, ***p<0.001. 
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3.3 Objective 2: Test molecular controls of breast cancer 
progression. Specific aim 2: Determine the role of 
VANGL1 overexpression using the 21T cell lines via 
stable transfection 
VANGL1 expression was previously found to be low in 21PT (ADH) and 
significantly higher in both 21NT (DCIS) and 21MT-1 (IDC) (Souter et al. 2010). To 
determine if VANGL1 plays a functional role in early breast cancer progression, 
VANGL1 was overexpressed in 21PT cells. The 3D morphology and invasive and 
migratory abilities of these cell lines were examined. 
3.3.1 VANGL1 is differentially expressed in the 21T cell lines 
VANGL1 mRNA expression was examined in the 21T cell lines. Total RNA was 
extracted from the 21PT, 21NT and 21MT-1 cell lines and subsequently reverse 
transcribed into cDNA. Primers specific to VANGL1 were used in a qRT-PCR to 
examine relative levels of VANGL1 among the three cell lines. VANGL1 mRNA 
expression was higher in the 21MT-1 cell line compared to both the 21PT and 21NT cell 
lines by 2.27-fold (p<0.001) and 2.48-fold (p<0.001) respectively; however, VANGL1 
mRNA levels were not found to be significantly different between the 21PT and 21NT 
parental cell lines (Figure 3.14). 
3.3.2 VANGL1 mRNA expression was increased in 21PT cells after 
transfection 
A VANGL1 expression vector containing a myc-His epitope was constructed and 
transfected into 21PT cells (21PT + VANGL1-myc). An expression vector containing 
only the full length version of VANGL1 (without the myc-His epitope) was also  
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Figure 3.14 VANGL1 mRNA levels in the 21T parental and derivative cell lines. For 
ease of comparison, the expression level for 21PT parental cells was set to 1. VANGL1 
mRNA expression is increased in the 21MT-1 parental cell line compared to both the 
21PT and 21NT cell lines as well as the 21PTci and 21NTci cells. VANGL1 expression 
was similar in the 21PT and 21NT parental cell lines and the 21PTci and 21NTci cells. 
mRNA expression levels were calculated as a ratio to the housekeeping gene GAPDH. 
To analyze mRNA expression a one-way ANOVA was performed with Tukey’s post hoc 
test and p<0.05 was considered statistically significant. ***p<0.001. 
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constructed and transfected into 21PT cells (21PT + VANGL1-stop). The expression 
vector alone (without VANGL1) was also transfected into 21PT cells (21PT + EV). qRT-
PCR was used to determine if levels of VANGL1 were increased in 21PT + VANGL1-
myc and 21PT + VANGL1-stop cells compared to empty vector controls. VANGL1 
mRNA was increased in the 21PT + VANGL1-myc cells by 8.12-fold (SE 0.92) 
compared to 21PT + EV (p<0.001) and increased in the 21PT + VANGL1-stop by 8.46-
fold (SE 0.87) compared to 21PT + EV (p<0.001) (Figure 3.15A). The 21PT + 
VANGL1-myc cell line had myc positivity shown by Western blot (Figure 3.15B). 
Additionally, VANGL1 mRNA expression was not increased in 21PT + WNT5A cells 
compared to the empty vector control (i.e. overexpression of transfected WNT5A did not 
increase expression of endogenous VANGL1, Figure 3.15A). 
3.3.3 VANGL1 overexpression increased migration but had no effect 
on invasion in 21PT cells 
To first assess the migratory ability of VANGL1 overexpression in 21PT cells, 
transwell migration assays were used. 21PT + EV, 21PT + VANGL1-myc, and 21PT + 
VANGL1-stop cells were placed in the upper chamber of a transwell migration system 
and allowed to migrate through the pores in order to reach FBS that was present in the 
lower chamber. VANGL1 overexpression increased 21PT cells’ ability to migrate from 
19.37 (SE 1.76) cells per field of view in 21PT + EV cells to 62.27 (SE 10.16) cells per 
field of view for 21PT + VANGL1-myc cells (p<0.05) and to 87.53 (SE 6.58) cell per 
field of view for 21PT + VANGL1-stop (p<0.01) (Figure 3.16A, 3.16C). To assess the 
invasive ability of VANGL1 overexpression in 21PT cells, 21PT + VANGL1 cell lines 
were used in a transwell invasion assay. 21PT + EV, 21PT + VANGL1-myc, and 21PT + 
VANGL1-stop cells were placed in the upper chamber of a transwell system and allowed  
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Figure 3.15 VANGL1 levels in 21PT cells after transfection with VANGL1-myc and 
VANGL1-stop. For ease of comparison, the expression level for 21PT + EV cells was 
set to 1. A) VANGL1 mRNA expression was increased in the 21PT + VANGL1-myc and 
21NT + VANGL1-stop cells compared to an empty vector control and 21PT + WNT5A. 
mRNA expression levels were calculated as a ratio to the housekeeping gene GAPDH. B) 
21PT + VANGL1-myc cells were positive for myc protein by Western blotting for myc 
protein expression at the predicted molecular weight for a Vangl1-myc fusion protein. To 
analyze mRNA expression a one-way ANOVA was performed with Tukey’s post hoc test 
and p<0.05 was considered statistically significant. ***p<0.001. 
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to invade through the pores in order to reach FBS that was present in the lower chamber. 
VANGL1 overexpression did not change the number of cells that invaded through the 
membrane (Figure 3.16B, 3.16C). 
3.3.4 VANGL1 overexpression did not change 3D morphology or 
growth of 21PT cells 
The 3D morphology of the 21PT transfectants was assessed using the modified 
3D morphology assay described in section 3.1. The 21PT + VANGL1-myc, 21PT + 
VANGL1-stop, and 21PT + EV cells were grown on top of 100% Matrigel in αHE media 
containing 2% Matrigel and 2% FBS for 12 days. VANGL1 overexpression had no effect 
on 3D morphology with respect to lumen formation, polarized colonies, and spherical 
colonies in either cell line compared to the empty vector control (Figure 3.17A, 3.17B). 
Overexpression of VANGL1 in 21PT cells did not have an effect on the number of nuclei 
per cell colony (Figure 3.17C). 
3.3.5 Recombinant Wnt5a protein increased migration but did not 
increase invasion of 21PT + EV and 21PT + VANGL1 cells 
To test the effect of both VANGL1 and WNT5A on breast cancer progression, 
recombinant Wnt5a protein was used as a treatment on 21PT cells that already 
overexpress VANGL1. To first assess treatment of recombinant Wnt5a on VANGL1 
overexpressing cells, the 21PT + EV and 21PT + VANGL1 cells were placed in the 
upper chamber of a transwell migration system (membranes with 8.0μm pores coated 
with 6μg of gelatin) and allowed to migrate through the pores in order to reach FBS 
(chemoattractant) that was present in the lower chamber. Each cell line was treated with 
0, 150, 300, and 600ng/mL recombinant Wnt5a. There was an increase in migration in 
both cell lines only when 600ng/mL recombinant Wnt5a was used (data not shown). Thus   
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Figure 3.16 VANGL1 overexpression increased migration but not invasion of 21PT 
cells. A) Transwell migration assay using 21PT + EV, 21PT + VANGL1-myc, and 21PT 
+ VANGL1-stop cells towards FBS for 5 hours. Both 21PT + VANGL1-myc and 21PT + 
VANGL1-stop cell lines exhibited an increase in the number of cells that migrated to the 
underside of the transwell membranes compared to 21PT + EV. C) Transwell invasion 
assay using 21PT + EV, 21PT + VANGL1-myc, and 21PT + VANGL1-stop cells 
towards FBS for 20 hours. Overexpression of VANGL1 had no effect on invasion of 
21PT cells C) Representative images used for counting the number of cells per field of 
view. To analyze the number of cells per field of view a one-way ANOVA was 
performed with Tukey’s post hoc test and p<0.05 was considered statistically significant. 
*p<0.05, **p<0.01. 
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Figure 3.17 VANGL1 overexpression had no effect on the 3D morphology or growth 
of 21PT cells. The 21PT + EV, 21PT + VANGL1-myc, and 21PT + VANGL1-stop cells 
were grown on top of 100% Matrigel in αHE + 2% FBS and 2% Matrigel for 12 days. 
Cell colonies were fixed, permeabilized, stained, and imaged using confocal microscopy. 
A) Representative cell colonies are shown at each day. Actin is shown in red, E-cadherin 
is shown in green, and the nuclear stain Hoechst is shown in blue. An overlay of all three 
channels is shown in the final set of panels. B) There was no effect from VANGL1 
overexpression on 3D morphology of 21PT cells. C) There was no effect of VANGL1 
overexpression on the number of nuclei per cell colony. Colony morphology was 
analyzed using one-way ANOVA followed by Tukey’s post hoc test and p<0.05 was 
considered statistically significant. Scale bar represent 30μm. 
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for following migration and invasion assays, only 600ng/mL was used. Recombinant 
Wnt5a treatment increased migration from 19.37 (SE 1.76) cell per field of view to 32.10 
(SE 1.99) cells per field of view in the 21PT + EV cell line (p<0.05) (Figure3.18A, 
3.18B). Likewise, recombinant Wnt5a treatment increased migration from 62.27 (SE 
10.16) cells per field of view to 108.5 (SE 8.26) cells per field of view in the 21PT + 
VANGL1-myc cell line (p<0.05) (Figure 3.18A, 3.18B). 
Next, to test the effect of both VANGL1 and WNT5A on breast cancer 
progression, recombinant Wnt5a protein was used as a treatment on 21PT cells that 
already overexpress VANGL1. To assess the treatment of recombinant Wnt5a on 
VANGL1 overexpressing cells, the 21PT + EV and 21PT + VANGL1-myc cells were 
placed in the upper chamber of a transwell system and allowed to invade through the 
pores in order to reach FBS (chemoattractant) that was present in the lower chamber. 
Recombinant Wnt5a protein was present in the upper and lower chambers at a 
concentration of 600ng/mL. Recombinant Wnt5a treatment had no effect on invasion of 
the 21PT + EV or the 21PT + VANGL1-myc (Figure 3.18A, 3.18B). 
3.4 Objective 2: Test molecular controls of breast cancer 
progression. Specific aim 3: Determine the role of 
WNT5A and VANGL1 on breast cancer progression via 
shRNA knockdown using the 21T cell lines 
3.4.1 WNT5A and VANGL1 mRNA levels were individually knocked 
down in 21MT-1 cells 
To further assess the role of non-canonical Wnt pathway during breast cancer 
progression, WNT5A and VANGL1 expression was knocked down in the 21MT-1 cell  
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Figure 3.18 Recombinant Wnt5a treatment increases migration but not invasion in 
the 21PT + VANGL1-myc cell line. A) Transwell migration assay using 21PT + EV and 
21PT + VANGL1-myc cells towards FBS for 5 hours with recombinant Wnt5a treatment. 
Wnt5a protein treatment increased the number of 21PT + EV and 21PT + VANGL1-myc 
cells that migrated to the underside of the transwell membranes compared to no Wnt5a 
treatment. B) Transwell invasion assay using 21PT + EV and 21PT + VANGL1-myc 
cells towards FBS for 20 hours with recombinant Wnt5a treatment. Wnt5a treatment had 
no effect on the number of 21PT + EV and 21PT + VANGL1-myc cells that migrated to 
the underside of the transwell membranes. C) Representative images used for counting 
the number of cells per field of view. To analyze the number of cells per field of view a 
one-way ANOVA was performed with Tukey’s post hoc test and p<0.05 was considered 
statistically significant. *p<0.05. 
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line using shRNA against both genes separately. WNT5A mRNA knockdown was 
achieved using one of the three shRNAs and VANGL1 knockdown was achieved with all 
three shRNAs in the 21MT-1 cell line. WNT5A expression was decreased by 2.23-fold 
(SE 0.076) compared to an off target knockdown control (p<0.05) (Figure 3.19A). In the 
most efficient knockdown, VANGL1 expression was decreased by 11.1-fold (SE 0.0064) 
compared to an off target knockdown control (p<0.01) (Figure 3.19B). 
3.4.2 WNT5A or VANGL1 knockdown had no effect on the 3D 
morphology or growth of 21MT-1 cells 
To assess the effect of WNT5A and VANGL1 knockdown on 3D morphology 
and cell growth, the 21MT-1 + shWNT5A, 21MT-1 + shVANGL1, and 21MT-1 + 
shLUC cells were grown in the 3D morphology Matrigel assay for 12 days. The 
proportion of cell colonies exhibiting lumen formation, polarized colonies, and spherical 
colonies (vs. non-spherical colonies) were assessed. The number of nuclei per colony was 
also assessed. Compared to the off target knockdown (21MT-1 + shLUC), WNT5A 
knockdown did not have an effect on 3D morphology (lumen formation, polarized 
colonies, spherical colonies) or the number of nuclei per cell colony at day 12 (Figure 
3.20A, 3.20B, 3.20C). Similarly, compared to the off target knockdown, VANGL1 
knockdown did not have an effect on 3D morphology or the number of nuclei per cell 
colony at day 12 (Figure 3.20A, 3.20B, 3.20C). 
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Figure 3.19 WNT5A and VANGL1 knockdown in 21MT-1 cells. A) Using a panel of 
three different shRNAs, WNT5A mRNA expression was knocked down in 21MT-1 cells. 
Only one shRNA effectively knocked down expression of WNT5A. B) Using a panel of 
three different shRNAs, VANGL1 mRNA expression was knocked down in 21MT-1 
cells. All three shRNAs were effective in knocking down VANGL1 expression. To 
analyze mRNA expression a one-way ANOVA was performed with Tukey’s post hoc test 
and p<0.05 was considered statistically significant. *p<0.05, **p<0.01. 
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Figure 3.20 WNT5A and VANGL1 knockdown had no effect on the 3D morphology 
or growth of 21MT-1 cells. The 21MT-1 + shLUC, 21MT-1 + shWNT5A, and 21MT-1 
+ shVANGL1 cells were grown on top of 100% Matrigel in αHE + 2% FBS and 2% 
Matrigel for 12 days. Cell colonies were fixed, permeabilized, stained, and imaged using 
confocal microscopy. A) Representative cell colonies are shown at each day. Actin is 
shown in red, E-cadherin is shown in green, and the nuclear stain Hoechst is shown in 
blue. An overlay of all three channels is shown in the final set of panels. B) There was no 
effect of either WNT5A or VANGL1 knockdown on 3D morphology of 21MT-1 cells. C) 
There was no effect of either WNT5A or VANGL1 knockdown on the number of nuclei 
per cell colony. Colony morphology was analyzed using one-way ANOVA followed by 
Tukey’s post hoc test and p<0.05 was considered statistically significant. Scale bar 
represent 30μm. 
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Chapter 4  
4 Discussion 
Worldwide, breast cancer continues to be a major health concern for women. In 
North America, although there has been a decreasing trend in the mortality rate over the 
last several decades, there will still be approximately 45 000 deaths due to metastatic 
breast cancer in 2012 (American Cancer Society 2012; Canadian Cancer Society’s 
Steering Committee on Cancer Statistics 2012). From a clinical perspective, there is a 
need to understand what drives the progression of breast cancer from earlier non-invasive 
lesions to an invasive phenotype.  
The 21T cell lines have been shown to represent a mammary tumor progression 
series and mimic specific stages of breast cancer in vitro and in vivo (Souter et al. 2010). 
Subsequent expression profiling has revealed significant differences in the non-canonical 
Wnt/PCP pathway members WNT5A and VANGL1 (Souter et al. 2010).  
WNT5A, the prototypical Wnt ligand which activates non-canonical Wnt 
signalling, has been shown to act as both an oncogene and tumor suppressor in different 
studies (Olson and Gibo 1998; Liang et al. 2003; Kremenevskaja et al. 2005; Leris et al. 
2005; Ying et al. 2007; Ying et al. 2008; Liu et al. 2008; Pukrop et al. 2006; Weeraratna 
et al. 2002; Kurayoshi et al. 2006). This dual effect of WNT5A may be due to the cellular 
context in which it is presented. For example, the effect of WNT5A may be due to the 
presence or absence of other Wnt pathway components (such as VANGL1).  
This study was designed to determine the cellular context that is required for 
WNT5A to act as an oncogene as opposed to a tumor suppressor in breast cancer using 
the 21T cell lines as a model for breast cancer progression. Results demonstrate that 
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WNT5A can act as an oncogene that drives progression towards a more invasive 
phenotype in a cell line representing DCIS (21NT) but not in a cell line representing 
ADH (21PT). Results also indicate that WNT5A’s effect in increasing invasion is 
partially due to a downstream effector of the PCP pathway, RHOA. Finally, results 
demonstrate that high VANGL1 expression alone is not sufficient to promote WNT5A-
induced progression to an invasive phenotype.  
4.1 The 21T cells grown in the “on-top” 3D morphology 
assay have distinct structural features and growth 
patterns 
Objective 1 was to improve the existing in vitro breast cancer progression model 
to assess 3D morphology with the 21T cell lines. Here, the 21T cell lines were 
characterized using the ―on-top‖ method and imaged using confocal microscopy. 
Consistent with the ―embedded‖ method that was previously used in our lab (Souter et al. 
2010), the 21T cells continue to have distinct 3D morphologies and growth patterns when 
used in the ―on-top‖ assay after similar endpoints (i.e. 12 days). The use of the 21T cells 
in an embedded 3D in vitro system has proven useful in distinguishing the 21T cells 
(21PT vs. 21NT vs. 21MT-1) based on 3D morphology as well as identifying potential 
regulators of progression (Souter et al. 2010). Embedding the 21T cell lines in Matrigel is 
expensive and preparing the cells for imaging is time consuming. However, seeding cells 
on top of Matrigel instead of embedding them has the potential to use fewer materials 
(Matrigel) and processing them for imaging via immunofluorescence can be faster than 
H&E staining of paraffin embedded Matrigel plugs. In addition, imaging is facilitated by 
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having the cells grow in a single plane in the ―on-top‖ assay. Thus, future work can take 
advantage of the ―on-top‖ assay for imaging of the 21T cell lines. 
4.2 PCP signaling promotes breast cancer progression in 
21NT cells 
To determine the role of PCP signalling in early breast cancer progression, 
WNT5A was overexpressed in 21PT and 21NT cells, representing ADH and DCIS 
respectively. WNT5A overexpression increased migration in both 21PT and 21NT cells, 
but only increased invasion in 21NT cells. 
WNT5A overexpression increased RHOA mRNA levels in both the 21PT and 
21NT cells. Subsequent knockdown of RHOA in WNT5A overexpressing 21PT and 
21NT cells decreased WNT5A-induced migration to levels similar to parental cells, thus 
implicating the PCP pathway in enhancing cell migration. This is consistent with the 
known role of PCP signalling in regulating the actin cytoskeleton and increasing 
migration. However, RHOA knockdown only partially decreased WNT5A-induced 
invasion in 21NT cells (WNT5A overexpression did not increase invasion in 21PT cells).  
An increase in migration alone is not sufficient for cancerous cells to acquire the 
ability to invade into the surrounding stroma. In this case, it appears that in 21NT cells 
some other gene(s) may be involved in allowing further progression to invasion. 
Furthermore, this work suggests that some aspect of WNT5A-induced invasion of 21NT 
cell occurs through a RHOA independent pathway. MMPs are related to the invasive 
phenotype, and induction of their expression may be a critical event in early breast cancer 
progression to invasion (Chang and Werb 2001). In human osteosarcoma cell lines, 
WNT5A has been shown to activate c-Src through the ROR2 co-receptor, which leads to 
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the expression of MMP-13 (Enomoto et al. 2009).  WNT5A has also been shown to 
induce the expression of MMP-1 in prostate cancer cells through the AP-1 axis by 
activation of PKC-δ and JNK (Yamamoto et al. 2010). WNT5A signalling is also linked 
to the expression of MMP-2 in renal cell carcinoma cell lines (Wright et al. 2009). 
Laminin c2, a subunit of the basement membrane protein laminin-5 (Miyazaki 2006), has 
been identified as a gene regulated by WNT5A (Yamamoto et al. 2009). Laminin c2 
contains a promoter region which binds JunD, an AP-1 element (Olsen et al. 2000). 
WNT5A has been shown to activate PKC and JNK, recruiting JunD to the AP-1 site of 
the laminin c2 promoter (Yamamoto et al. 2009). Abnormal laminin c2 expression has 
been detected at the invasive front of gastric and colon cancer, suggesting that laminin c2 
is involved in invasion, although the mechanism remains unclear (Koshikawa et al. 1999; 
Pyke et al. 1995). Therefore, abnormal WNT5A signalling via the AP-1 axis may be 
involved in invasion through the expression of MMPs and laminin c2, in addition to 
increased cell migration resulting from a rearrangement of the actin cytoskeleton through 
the downstream effector RHOA. 
 In the present study, VANGL1 overexpression alone was capable of enhancing 
migration of 21PT cells, but had no effect on 21PT cell invasion, 3D morphology, or 
growth, similar to the effects of WNT5A overexpression. This is consistent with its 
known role as a core PCP component. However, VANGL1 has previously been shown to 
increase invasion in colorectal cancer by recruiting PKC-δ to the plasma membrane and 
enhancing AP-1 transcriptional activity (Kho et al. 2009).  
High VANGL1 expression was initially hypothesized as the context in which 
WNT5A can act as a promoter of breast cancer progression. However, analysis of mRNA 
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levels in the 21T cell lines revealed that VANGL1 expression was similar in both 21PT 
and 21NT cells, and upon WNT5A overexpression in these cell lines, only the 21NT cells 
invaded more in a transwell invasion assay. In addition, in 21PT cells that overexpressed 
VANGL1, recombinant Wnt5a treatment did not increase invasion. Thus, results 
demonstrate that although high VANGL1 expression induces cell migration of 21PT 
cells, high VANGL1 alone is not sufficient to promote WNT5A-induced progression to 
an invasive phenotype.  
It is conceivable that, in 21PT cells, WNT5A and VANGL1 do not increase 
invasion because of a missing component in the AP-1 axis that is downstream of 
VANGL1 or PKC-δ. Future studies will examine downstream components of the AP-1 
axis in 21PT and 21NT cells to determine if this pathway is necessary for WNT5A- or 
VANGL1-induced invasion. 
4.3 Genes that could determine the cellular context 
required for WNT5A to promote progression to invasion 
There are 22 defined mitogen-activated protein kinase kinase kinases (MAP3Ks) 
and over 40 total mitogen-activated protein kinases (MAP2Ks and MAPKs) (Cuevas et 
al. 2007). This large network of MAPKs represents 8% of the human kinome. 
Downstream components of the MAPK signalling network, including JNK, p38, and 
extracellular signal-regulated kinase 5 (ERK5) are activated in a number of cancers, such 
as breast, prostate, squamous and hepatocellular carcinoma (Davidson et al. 2006; Hui et 
al. 2008; McCracken et al. 2008; Sticht et al. 2008; Montero et al. 2009; Zen et al. 2009; 
Wang et al. 2010; Wagner and Nebreda 2009).  
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Activation of these downstream MAPKs is controlled by upstream MAP3Ks that 
have also been shown to be dysregulated in cancer cells. For example, the MAP3K Tpl2 
has been shown to be overexpressed in 40% of human breast cancers (Sourvinos et al. 
1999). An activating mutation of Tpl2 was found in a patient with basal-like breast 
cancer and cells containing this Tpl2 mutation were increased in the metastatic tissue 
(Ding et al. 2010). Also, the MAP3Ks, MEKK3 and A-Raf, are overexpressed in non-
small-cell lung cancer (Lee et al. 2010b). 
Recently, using MDA-MB-231 cells in an orthotopic xenograft model to screen 
the function of seven MAP3Ks in controlling tumor metastasis, MAP3K2 (also known as 
MEKK2) was identified as a potential regulator of metastasis. Specifically, knocking 
down expression of MAP3K2 with shRNA inhibited metastasis of MDA-MD-231 tumors 
in SCID mice (Cronan et al. 2012). Inhibition of WNT signalling in MDA-MB-231 cells 
also decreased invasion in a β-catenin independent manner (Klemm et al. 2011).  
MAP3K2 expression is 1.7 to 1.8 fold higher in 21NT cells than in 21PT cells 
(Souter et al. 2010). This differential expression of MAP3K2 in the 21NT and 21PT cell 
lines could be responsible for the differing effects of WNT5A on invasion and may 
provide the cellular context that allows WNT5A to induced progression to invasion 
(Figure 4.1). Future work will examine the role that MAP3K2 plays in response to 
WNT5A overexpression in the 21T cell lines. 
4.4 WNT5A during canonical Wnt/β-catenin dependent 
signalling 
There is conflicting evidence as to whether WNT5A antagonizes or agonizes β-
catenin dependent signalling. An early observation of WNT5A was its ability to inhibit  
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Figure 4.1 Speculative mechanism of differential WNT5A effect in the 21T cell lines. 
WNT5A overexpression increases migration in both 21PT (ADH) and 21NT (DCIS) 
through a RHOA dependent pathway. Additionally, due to high levels of MAP3K2 
(Souter et al. 2010), WNT5A overexpression in 21NT cells increases invasion in an AP-1 
dependent manner. This effect is not seen in 21PT cells due to low MAP3K2.  
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the canonical Wnt/β-catenin dependent pathway (Torres et al. 1996) by antagonizing the 
effect of Wnt1. Studies in WNT5A knockout mice also revealed that β-catenin signalling 
was enhanced (Topol et al. 2003; Sato et al. 2010). Several mechanisms can explain this 
possible inhibitory effect of WNT5A on β-catenin dependent signalling. For example, 
WNT5A has been shown to inhibit β-catenin dependent gene expression through the 
activation of Nemo-like kinase (NLK) whereby WNT5A activates CaMK through the 
activation of TGF-β-activated kinase (TAK) (Ishitani et al. 1999; Ishitani et al. 2003). It 
has also been shown that WNT5A can activate PKCα, leading to the phosphorylation of 
RORα. Phosphorylated RORα inhibits β-catenin dependent gene expression through the 
inhibition of the recruitment of co-activators to the promoter regions of target genes (Lee 
et al. 2010a). WNT5A has been shown to affect the stability of β-catenin by inducing the 
expression of an ubiquitin E3 ligase (Siah2), a protein that degrades β-catenin (Topol et 
al. 2003). Finally, WNT5A may inhibit β-catenin signalling at the level of the receptor. 
Canonical and non-canonical Wnts have been shown to use a common mechanism to 
activate completely different co- receptors (i.e. ROR1/2 and LRP5/6), while acting 
through similar Fzd receptors (Grumolato et al. 2010). Thus, WNT5A can prevent 
WNT3A binding to Fzd2, inhibiting signalling through LRP6 and β-catenin (Sato et al. 
2010). 
WNT5A has also been shown to stimulate β-catenin signalling in some cases. For 
example, overexpression of WNT5A and Fzd5 or Fzd4 in Xenopus embryos induced 
expression of Wnt/β-catenin target genes (He et al. 1997; Umbhauer et al. 2000). In 
addition, overexpression of Fzd4 and LRP5 enabled WNT5A to stabilize β-catenin 
protein and allow it entry into the nucleus, where it complexes with T-cell 
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factor/lymphoid enhancer factor transcription factors (Mikels and Nusse 2006). This 
suggests that receptor expression may be one particular cellular context that dictates the 
output of WNT5A. However, the stimulatory effects of WNT5A on the β-catenin 
signalling have only been shown under conditions where the receptors are overexpressed. 
It is unclear if WNT5A can have agonistic effects on the β-catenin pathway under normal 
physiological conditions. However, it may be necessary to consider WNT5A-induced 
activation of β-catenin signalling during pathological conditions where expression of 
canonical Wnt receptors is increased. 
In the present study the stabilization of β-catenin and signalling through β-catenin 
dependent processes was not examined. It is conceivable that WNT5A overexpression 
may have an effect on β-catenin which in turn may effect cancer progression in the 21T 
cell lines. However, aberrant β-catenin signalling is primarily involved in proliferation, 
tumor growth, and tumor initiation, and since growth of the 21T cells was not affected by 
WNT5A overexpression, it seems unlikely that altered β-catenin function played a role in 
WNT5A-induced breast cancer progression in these cells. 
4.5 Limitations and future work 
The effect of WNT5A and VANGL1 knockdown was examined in the 21MT-1 
cell line (representing invasive mammary carcinoma), but only growth and 3D 
morphology were measured, finding no effect. However, there was only a 2.23-fold 
decrease in WNT5A expression due to shRNA knockdown; whereas in the parental cell 
lines, WNT5A expression is much lower in the 21NT cells (109.1-fold). For future work 
with the 21MT-1 cells, in order to conclusively establish the importance of WNT5A 
expression to malignancy, the knockdown in WNT5A expression should preferably be to 
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a level similar to 21PT and 21NT cells. This could be accomplished by using shRNAs 
that target different regions of the WNT5A mRNA. Another limitation of the knockdown 
studies with the 21MT-1 cells is that they are lacking an effective measure of 
invasiveness. This is due to an intrinsic limitation of the 21MT-1 cells; 21MT-1 cells are 
too big to fit through 8.0μm and 12.0μm pores of the transwell membrane. The 21MT-1 
cells have been shown to be more invasive than the 21PT and 21NT cells in a time lapse 
invasion assay in which the cells were embedded in Matrigel (Souter et al. 2010). Future 
studies should take advantage of this assay using 21MT-1 + shWNT5A and 21MT-1 + 
shVANGL1 cells in order to assess the effect of WNT5A and VANGL1 knockdown on 
invasiveness of this metastatic breast cancer cell line. 
4.6 Summary 
This study provides evidence that WNT5A can promote progression during an 
early stage of breast cancer. WNT5A overexpression increased invasion in a cell line 
representing DCIS (21NT), but not in a cell line representing ADH (21PT). It was 
hypothesized that this differential effect of WNT5A on invasion may be due to the 
presence or absence of other non-canonical Wnt/PCP pathway genes such as VANGL1. 
Overexpression of VANGL1 alone or with recombinant Wnt5a protein did not increase 
invasion of 21PT cells. VANGL1 mRNA levels were also found to be similar in both 
21PT and 21NT cells. Thus VANGL1 was likely not responsible for WNT5A’s 
differential effect on invasion. 
 Future studies should examine other genes that establish the cellular context that 
is required for WNT5A’s invasive properties. One possible gene is MAP3K2. MAP3K2 
is involved in the AP-1 axis and activates JNK, which is downstream of both WNT5A 
88 
 
and VANGL1. MAP3K2 is expressed in higher levels in the 21NT cells compared to the 
21PT cells and has been shown to promote breast cancer metastasis in MBA-MD-231 
derived tumors. 
Understanding the role of WNT5A and PCP signalling during progression is 
complicated when considering progression is not only an epithelial driven process. 
However, this study sheds light on the role that WNT5A and PCP signalling plays on 
breast epithelial cells during the transition to an invasive phenotype. With this work and 
continued research in this area, it is hopeful that a more complete understanding of the 
cellular context that allows WNT5A to induce progression is elucidated. 
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